Ionic liquid containing pluronic gel for enhanced dermal delivery of cyclosporine a
Patent Information
- Application Number
- IN202211039074
- Authority / Receiving Office
- IN · IN
- Patent Type
- Patents
- Current Assignee / Owner
- Filing Date
- 2022-07-07
- Publication Date
- 2026-07-13
- Estimated Expiration
- 2042-07-07
AI Technical Summary
The challenge lies in enhancing the dermal delivery of cyclosporine A, a high molecular weight peptide with poor aqueous solubility and hydrophobicity, across the skin for treating conditions like psoriasis, as existing methods face limitations in permeation due to the skin's barrier properties.
A composition comprising pluronic gel mixed with choline and geranic acid ionic liquids (CAGE) in a 2:1 ratio, along with PEG400, is developed to enhance the solubility and permeation of cyclosporine A, utilizing shear-thinning pseudoplastic behavior and interaction with epidermal lipids for improved skin penetration.
The CAGE-pluronic gel formulation significantly increases the storage modulus, decreases loss modulus, and enhances the permeation of cyclosporine A across intact skin, achieving higher cumulative amounts and prolonged release, with improved pharmacokinetic parameters and efficacy in treating psoriasis.
Abstract
Description
FIELD OF THE INVENTION: The present invention relates to the development of a composition comprising ionic liquid containing pluronic gel for enhanced dermal delivery of cyclosporine A (CsA) for topical application. The novel composition according to the invention comprises of permeation enhancers as choline and geranic acid (CAGE) ionic liquids (ILs) in pluronic gel. Choline and geranic acid (CAGE) ionic liquids in 2:1 ratio is mixed with Pluronic gel (22.7 % w / v) and PEG400 (45%) to prepare the formulation of cyclosporine A (CsA). BACKGROUND OF THE INVENTION Cyclosporine A (CsA) is a cyclic polypeptide composed of 11 amino acids that has shown immune modulation activity [1]. It has been indicated for the treatment of various dermatological diseases including psoriasis, atopic dermatitis and alopecia areata and for systemic conditions including prevention of organ rejection after transplantation [2]. The long-term systemic administration of cyclosporine A causes serious side effects, including renal dysfunction, chronic nephrotoxicity and hypertension [3]. Cyclosporine A (CsA) is commercially available as oral capsules, intravenous preparations, and eye drops [4]. The feasibility of topical application of cyclosporine A has been explored. However, the unfavorable physicochemical properties of cyclosporine A (MW: 1202Da; log P ≈ 3; poor water solubility) hinder its permeation across the outer layer of skin, stratum corneum (SC) [5]. The stratum corneum made of corneocytes and lipid matrix forms a potential barrier for the permeation of macromolecules. In order to enhance the permeation, chemical enhancers were investigated such as ethanol, ethyl oleate, Transcutol, propylene glycol, azone [6], decylmethylsulfoxide [7] and skin penetrating peptides [8,9]. Also, physical enhancing technique were evaluated, particularly electroporation
[10] and ultrasounds
[11] . Among nanocarriers, nanoparticles [12-14], Ultraflexible lipid vesicles [4] and liposomes
[15] were also investigated. Some authors have also evaluated the possibility to deliver cyclosporine A by liquid crystalline systems
[16] . Therefore, there is an unmet need for the development of a composition for enhanced dermal delivery of cyclosporine A (CsA).Various enhancement techniques have been investigated to improve the skin permeation of active molecules which are otherwise impermeable through skin. The enhancement techniques are generally classified as chemical and physical techniques. While chemical permeation enhancers are simple systems that can be included within the topical formulations, physical permeation enhancers such iontophoresis, microneedle device, ultrasound system are complex in nature with limitations on applicability
[17] . Chemical permeation enhancers would either alter the thermodynamic activity of active compounds within the formulation, and / or improve drug diffusivity by altering the skin barrier [18, 19]. The most widely used categories of chemical enhancers include alcohols, fatty acids, terpenes, among others [20-22]. Among the fatty acids, oleic acid is most widely used as permeation enhancer
[23] . More recently, ionic liquids have shown potential in skin permeation enhancement of active compounds
[24] . Hence, in this present invention, we report the investigation of the effect of fatty acids (oleic acid and palmitic acid) and ionic liquids (choline bicarbonate and geranic acid) on the skin permeation of cyclosporine A. Few of the related prior are listed below. WO2015 / 066647 discloses composition containing ionic liquids for its applications with improved transdermal transportation of therapeutic, prophylactic, or diagnostic agents. WO2018 / 044920 is related to topical compositions which includes complexes of macromolecular anions and cations with alkyl chains which are typically neutral charge, due to counterions such as NaCl and a liquid at room temperature and standard pressure for enhanced penetration across the skin barrier (stratum corneum) for its application in treatment of skin conditions. The Macromolecule anions may include nucleic acids, peptides, proteins and / or carbohydrates, such as hyaluronic acid. WO2019 / 183142 discloses anti-microbial and anti-inflammatory topical pharmaceutical composition containing ionic liquid, which further comprises of choline cation and fatty anion which includes geranic acid in the ratio of 1:1 to 1:4 along with pharmaceutically acceptable solvent and gelling agent for use in treatment of rosacea. WO2020 / 205409 discloses application of ionic liquid method for drug delivery, wherein the ionic liquid comprises of i) a hydrophobic anion comprising a carboxylic acid having a pKa of at least 4.0 and / or a LogP of at least 1.0; and ii) a cation comprising a quaternary ammonium. The two drugs assessed in the study includes acarbose and ruxolitnib form various CAGE compositions. Other anionic alternatives such as citonellic acid, glutaric acid and choline cationic alternatives like choline octanoate were also analyzed. Oleic acid (OA, C18; unsaturated) and palmitic acid (PA, C16; saturated) have been found to disrupt the ordered lipid matrix with SC causing permeation enhancement [25-27]. Ionic liquids are the ionic compounds with melting point below 100 °C, have shown interesting properties that can be controlled by the tunability of both cation and / or anion, with a multidisciplinary application in chemical, biological, engineering, environmental and material sciences
[28] . They possess dual capability of dissolving both polar and nonpolar species, without getting evaporated even at high temperatures. The use of ILs can markedly improve the pharmacokinetic and pharmacodynamics properties of drugs
[29] . To this, among different ILs, the application of choline (C6; MW: 165.19Da, cation) and geranate (C10; MW: 168.23Da; anion) (CAGE 1:2 M) was reported to enhance the permeation of proteins such as bovine serum albumin (MW: ≈66KDa), ovalbumin (MW: ≈45KDa) and insulin (MW: 5.8KDa) without the use of any physical / chemical penetration enhancement techniques, across the porcine skin
[30] . Figure 1 shows the molecular structures of cyclosporine A, OA, PA and CAGE. Topical formulations include liquid and semisolid preparations. The semisolid preparations such as hydrogels and organogels provide ease of application. Therefore, poloxamer is used to prepare organogel containing cyclosporine A and permeation enhancers. Poloxamers are non-ionic block copolymers of polyoxythylene-polypropylenepolyoxythylene (PEOn-PPOm-PEOn)
[31] . Pluronic F-127 (also known as poloxamer 407; P407; copolymer PEO106-PPO70-PEO106), is non-toxic and exhibits a low viscosity below 4°C. PF-127 gels present unique characteristics including the gelation behavior and micellar properties. These characteristics make these polymers to be effective vehicles for delivering drugs through topical and transdermal routes as these systems exhibit excellent drug permeability by diffusion through the lipid intracellular matrix and by disorganization of skin
[32] . In this regard, several drugs such as 5-Fluorouracil and Adriamycin
[33] , ketoprofen
[34] , diclofenac
[35] , ondansetron
[36] , testosterone
[37] , promethazine
[38] , methimazole
[39] , curcumin
[40] have been entrapped in Pluronic gels with or without enhancers, that penetrate or retained across or into the skin in significant amounts, by altering the skin barrier. The objective of this study was to investigate the feasibility of transdermal delivery of cyclosporine A across intact skin using permeation enhancers, including palmitic acid and oleic acid or CAGE-Pluronic gel. SUMMARY OF THE INVENTION The present invention relates to the development of a composition for enhanced dermal delivery of cyclosporine A using pluronic gel containing ionic liquids (ILs) formulation. The delivery of high molecular weight peptide therapeutics through skin is a challenge. cyclosporine A is a cyclic undecapeptide with high molecular weight (1202 Da), hydrophobicity (log P 3.6) and poor aqueous solubility (27 μg / ml) through skin in a noninvasive fashion for its implication in condition like psoriasis. The objective of the present invention is intended to enhance to enhance the skin permeation of cyclosporine A using pluronic gel containing ionic liquids (ILs) formulation. The ionic liquids comprise of choline and geranic acid (CAGE). Presence of CAGE ionic liquids and polyethylene glycol (PEG) mixture enhanced solubility of cyclosporine A. The cyclosporine A-loaded CAGE-gel showed shear-thinning pseudoplastic behavior. Choline and geranic acid (CAGE) ionic liquids in 2:1 ratio is mixed with Pluronic gel (22.7 % w / v) and PEG400 (45%) to prepare the formulation. The influence of co-treatment of chemical permeation enhancers (oleic acid, palmitic acid, CAGE) and CAGE-pluronic gel on permeation of cyclosporine A across intact skin was evaluated. The mechanism of cyclosporine A skin permeation enhancement by oleic acid, palmitic acid, CAGE and CAGE-pluronic gel was investigated using FTIR spectroscopy, scanning electron microscopy and thermal analysis techniques. The prepared CsA-CAGEP gel is characterized for various parameters including clarity, pH, drug content, contact angle, swelling index using FTIR, NMR spectroscopy, powder XRD, DSC and SEM. CsA-CAGE-P (cyclosporine A in Pluronic gel with ionic liquids) significantly (p<0.05) increased the storage modulus (G') by 4.5-fold and decreased loss modulus (G") by 6-fold compared to blank gel, respectively. The viscosity measurement at varying shear rate 0.1 s 1 - 500 s -1 showed shear-thinning behavior of CsA-CAGE-P. Results from permeation studies showed cyclosporine A passively did not permeate across intact skin after 48h. However, cumulative amount of cyclosporine A permeated across intact skin treated with oleic or palmitic acid was found to be 244 ± 4 μg / cm 2 and 1236 ± 17 μg / cm 2 respectively. The application of CAGE-P gel enhanced the permeation of cyclosporine A across intact skin by 1.3 - fold. Spectroscopic and thermal analysis showed the interaction of CAGE with epidermal lipids to enhance cyclosporine A permeation. Pharmacokinetic analysis after topical application of cyclosporine A (40 mg / kg) showed that the Cmax and t1 / 2 increased by 2.61 and 1.41 - fold with the application of CAGE-P gel compared with other groups. Topical application of CsA-CAGE-P gel (10 mg / kg) on imiquimod induced psoriatic plaque model reduced the symptoms of psoriasis. Taken together, CAGEPluronic gel can be developed for enhanced transdermal delivery of cyclosporine A. BRIEF DESCRIPTION OF ACCOMPANYING DRAWINGS The foregoing and further objects, features and advantages of the present subject matter will become apparent from the following description of exemplary embodiments with reference to the accompanying drawings. It is to be noted, however, that the appended drawings illustrate only typical embodiments of the present subject matter, and are therefore, not to be considered for limiting of its scope, for the subject matter may admit to other equally effective embodiments. Figure 1: Chemical structures of cyclosporine A, oleic acid, palmitic acid, geranic acid and choline bicarbonate. Figure 2: Rheological analysis of formulations. Change in complex viscosity (a), storage modulus (b) loss modulus (c) and change in viscosity with varying shear rate (d) for CsAloaded CAGE-gel formulations (F1-F5) with the increase in temperature or rate of shear. Data represents mean ± standard deviation (n=3-4). '*' represents that the value is significantly different at p < 0.05 compared to all the other groups. Figure 3: Proton NMR spectra in deuterated acetic acid using the Bruker TOPSPIN software (version 4.0.3). Presence of amide (-NH) and chemical shift in delta value (0.3ppm) confirms the loading of CsA in gel. CsA-CAGE-P- CsA in Pluronic gel with ionic liquids, CAGE-P- blank gel. Figure 4: Representative powder X-ray diffractogram (a), FTIR spectra (b) and DSC thermograms (c) of gel formulation with different ingredients. Swelling behavior of blank (CAGE-P gel) and CsA in Pluronic gel with ionic liquids (CsA-CAGE-P gel) formulation in phosphate buffered saline (pH 7.4, 37°C) (d). CsA- cyclosporine A. Data are presented as mean ± SD (n = 4). Figure 5: In vitro release profile of cyclosporine A (CsA) from formulations including CsA solution (free CsA), choline and geranate mixture (CAGE) and Pluronic gel with ionic liquids (CsA-CAGE-P gel) (a). Scanning electron microscopic (SEM) images of CsACAGE-P gel formulation (b). Measurement of contact angle for gel using goniometer on the intact skin (c) and change in contact angle with time (d). Insets represents representative digital images. Results are presented as mean ± SD (n = 4). Asterisk (*) represents that the value is significantly different at p < 0.05 compared to CAGE-P gel formulation. Figure 6: Drug release data fitted to various kinetic models for CsA-loaded organogel formulation. Zero-order kinetics (a), 1 st-order kinetics (b), Higuchi model (c) and Korsmeyer Peppas (d). Figure 7: Permeation profile of cyclosporine A (CsA) (a) and its retention within skin, after 48 h of applied using different formulations (b). Data represent mean ± SD, where n = 4 - 6. Asterisk (*) represents that the value is significantly different at p < 0.05 compared to all the other groups. "**" represents that the retention of CsA in SC is significantly more at p< 0.05 compared to PA or CAGE or 1% CsA-CAGE-P gel treated groups. "#" represnets that the retention of CsA in viable epidermis is significantly more at p< 0.05 compared to all the other formulation treated groups, excpet CAGE. CAGE - choline and geranate ionic liquids; CsA-CAGE-P gel - CsA in Pluronic gel with ionic liquids. Figure 8: FTIR spectra (a) and DSC thermograms (b) for stratum corneum (SC) treated with enhancers at different time points. Scanning electron microscopic (SEM) images for intact (c); tape-stripped skin (removal of SC); stratum corneum (e) without any treatment. SEM images for SC treated with oleic acid (OA), palmitic acid (PA); CAGE-mixture and CAGE-Pluronic gel, arranged in rows from (left to right) for 2 h, 12 h and 48 h respectively. The treated skin samples show cracks (2 h treatment), hair follicles (dotted circle, 12 h treatment) and skin furrows (dotted arrows; 12 and 48 h treatment). Scale bar represents 50 μm. Figure 9: TEWL and LDF (a) and irritancy index (b) values for intact and treated skin measured after 2h of application of different formulations with mean ± SD, where n = 4. '*' and '**' represents that the value is significantly different at p < 0.05 compared to all the other groups. Irritation index was calculated by dividing the values for LDF test by LDF control. Control - CsA dispersed in PBS + ethanol solution mixture; PA - palmitic acid; CAGE - choline and geranate ionic liquids; CsA-CAGE-P gel - CsA in Pluronic gel with ionic liquids. Figure 10: Plasma concentration after topical application of CsA in combination with PBS + ethanol solution mixture or PA or CAGE or CAGE-pluronic gel, with mean ± SD, where n = 4. '*' represents that the value is significantly different at p < 0.05. Control - CsA dispersed in PBS + ethanol solution mixture; PA - palmitic acid; CAGE - choline and geranate; CsA-CAGE -P gel - CsA loaded Pluronic gel with ionic liquids. Figure 11: Representative images captured of the dorsal skin in IMQ-induced psoriasis rat model (2 - 8 days) and without any treatment or after treatment with CsA-CAGE-P gel or CsA i.v. (9 - 16 days). Figure 12: Change in body weight (a), TEWL (b) and blood flow (c) from 1 to 8 days (psoriasis inducement) and without any treatment or subsequent treatment with CsACAGE gel or CsA i.v. from 9 - 16 days. Values represent mean ± SD, where n = 4. Asterisk (*) represents that the value is significantly different at p < 0.05 compared to all the other groups. TEWL - transepidermal water loss. IMQ - imiquimod; CsA - cyclosporine A; CAGE - choline and geranate ionic liquids; i.v. - intravenous route. Figure 13: Measurement of percentage water intake (a) and food intake (b) without any treatment or subsequent treatment with CsA-CAGE gel or CsA i.v. from 9 - 16 days. Evaluation of spleen length in the course of IMQ-induced psoriasis. Visual examination shows increased length and width of the spleen between days 4 to 8 (c). Spleen length (d)Values are presented as mean ± SD (n = 4), except for control where n = 3). Asterisk (*) represents that the value is significantly different at p < 0.05 compared to other groups. Control (1), IMQ-application (2); No-treatment (3); CsA-CAGE-P gel (4) and CsA-i.v. (5). Figure 14: Representative infrared thermal images of rats induced with psoriasis (2 - 8 days) and after treatment with CsA-CAGE gel or CsA i.v. or without any treatment (9 - 16 days). Figure 15: PASI scores of the plaque psoriasis rat model. IMQ cream was applied on the shaved dorsal skin for 8 consecutive days. Rats were either not treated or treated with topical application of CsA-CAGE-P gel or CsA i.v. formulation for 8 - 16 days. PASI score of erythema (a) and scaling (b) of skin lesion. Erythema and scaling were scored on a scale from 0 -4, indicating (0, none; 1, slight; 3, marked; 4, very marked). The skinfold on the back of rat was measured to quantify the thickness of skin caused by IMQ application or with or without CsA-CAGE-P gel or CsA i.v. treatment (c). The effect of CsA-CAGE-P gel or i.v. formulation on IMQ induced splenomegaly was measured by spleen to body weight ratio (spleen index) and representative images of spleen in each group (d). Values are represented as mean ± SD, where n =4. Asterisk (*) represents that the value is significantly different at p < 0.05 compared to all the other groups. Figure 16: Representative brightfield (1 st row) and hemotoxylin and eosin (H&E) stained (2 nd row) images for control (a, f); IMQ application (b, g); no-treatment (c, h); CsA-CAGE gel (d, i) and CsA i.v. (e, j). Red line indicates the epidermal thickness. Mean of epidermal thickness was calculated based on 10-15 random site measurements. SC - stratum corneum; VE - viable epidermis. Scale bar represents 100 μm. Figure 17: Permeation profile of cyclosporine (CsA) (a) and its retention across rat skin (b). Values represent mean ± SD, where n = 4. Asterisk (*) represents that the value is significantly different at p < 0.05 compared to all the other groups. Hash (#) represents that the value is significantly different at p < 0.05 compared to CsA i.v. treatment group. DETAILED DESCRIPTION OF THE INVENTION The following presents a detailed description of various embodiments of the present subject matter with reference to the accompanying drawings. The embodiments of the present subject matter are described in detail with reference to the accompanying drawings. However, the present subject matter is not limited to these embodiments which are only provided to explain more clearly the present subject matter to a person skilled in the art of the present disclosure. As used herein, the singular forms "a", "an" and "the" are intended to include the plural forms as well, unless expressly stated otherwise. It will be further understood that the terms "includes", "comprises", "including" and / or "comprising" when used in this specification, specify the presence of stated features, integers, steps, operations, elements, and / or components, but do not preclude the presence or addition of one or more other features, steps, operations, elements, components, and / or groups thereof. As used herein, the term "and / or" includes any and all combinations of one or more of the described ingredients having similar properties. As used herein, the term "pharmaceutical composition" refers to the active agent in combination with a pharmaceutically acceptable carrier e.g., a carrier commonly used in the pharmaceutical industry. The phrase "pharmaceutically acceptable" is employed herein to refer to those compounds, materials, compositions, and / or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit / risk ratio. In some embodiments of any of the aspects, a pharmaceutically acceptable carrier can be a carrier other than water. In some embodiments of any of the aspects, a pharmaceutically acceptable carrier can be a cream, emulsion, gel, liposome, nanoparticle, and / or ointment. In some embodiments of any of the aspects, a pharmaceutically acceptable carrier can be an artificial or engineered carrier, e.g., a carrier that the active ingredient would not be found to occur in in nature. As used herein, the term "administering," refers to the placement of a compound as disclosed herein into a subject by a method or route which results in at least partial delivery of the agent at a desired site. Pharmaceutical compositions comprising the compounds disclosed herein can be administered by any appropriate route which results in an effective treatment in the subject. The term "effective amount" means an amount of a composition sufficient to provide at least some amelioration of the symptoms associated with the condition. In one embodiment, the "effective amount" means an amount of a composition would decrease the markers or symptoms of the condition in a subject having the condition. The term "statistically significant" or "significantly" refers to statistical significance and generally means two standard deviations (2SD) or greater difference. Described herein, in certain embodiments of the invention, are composition and methods for enhanced dermal delivery of a drug for treatment or infectious skin condition associated with it. In some embodiments, the drug in the formulation described herein includes, but are not limited to the categories and examples of drugs and alternative forms of these drugs such as alternative salt forms, free acid forms, free base forms, and hydrates: such as immunosuppressive agents (e.g., cyclosporine, azathioprine, mizoribine, and FK506 (tacrolimus)). In the preferred embodiments, the drug selected is cyclosporine A (CsA). In some embodiments, the composition comprises of permeation enhancers as ionic liquids (ILs). In some embodiments the ionic liquid comprises of a cation and a fatty acid anion. In some embodiments the cation is a choline cation, and the fatty acid anion is geranic acid (CAGE). In some embodiments the composition further comprises of gelling agent, a viscosity modifying agent or a combination thereof. In some embodiments, the gelling agent or the viscosity modifying agent is also a bulking agent. In some embodiments, the gelling agent or viscosity modifiers includes, but not limited to, as different poloxomers, polyvinyl alcohol, polyethylene oxide, carbopols, or celluloses such as ethyl cellulose, hydroxyl ethyl cellulose, hydroxyl propyl cellulose, hydroxyl propyl methyl cellulose, sulfoxides or similar compounds such as dimethyl sulfoxide, dimethylsulfoxide, dimethylacetamide, dimethylformamide, pyrrolidones such as 2pyrrolidone, N-methyl-2- pyrrolidone, l-lauryl-2- pyrrolidone, alcohols such as ethanol, 1octanol, 1-hexanol, 1-decanol, lauryl alcohol, linolenyl alcohol, glycols such as propylene glycol, butane-1,2-diol, polyethylene glycol 400, urea and derivatives urea, such as 1dodecylurea, 1-dodecyl-3-methylurea, 1- dodecyl-3-methylthiourea, azone and azone like molecules such as (laurocapram; 1- dodecylazacycloheptan-2-one), 1-alkyl- or 1alkenylazacycloalkanones, enzymes acid phosphatase, calonase, papain Iminosulfuranes S, S-dimethyl-N-(5-nitro-2-pyridyl) iminosulfurane, S,S-dimethyl-N- (4-bromobenzoyl) iminosulfurane, cyclodextrins such as 2- hydroxypropyl-cyclodextrin, ethylated-b-cyclodextrin, fatty acid esters such as cetyl lactate, butyl acetate, isopropyl myristate, Fatty acids alkanoic acids, oleic acid, lauric acid, capric acid, surfactants such as sorbitan monopalmitate, sorbitan trioleate, cetyl trimethyl ammonium bromide, sodium lauryl sulfate, terpenes such as limonene, nerolidol, farnesol, carvone, menthone, polymers such as b-D-glucopyranosyl-terminated oligodimethylsiloxanes, 1-alkyl-3-b-D-glucopyranosyl-1,1,3,3-tetramethyldisiloxanes, Monoolein, Oxazolidinones 4-decyloxazolidin-2-one, 3-acetyl-4-decyloxazolidin-2-one, carbomer, methyl cellulose, sodium carboxyl methyl cellulose, carrageenan, colloidal silicon dioxide, guar gum, gelatin, alginic acid, sodium alginate, and fumed silica. In the preferred embodiments the pluronic gel or poloxomers is Kolliphor P407 oxyethylene 71.5-74.9 % (Lutrol F127 or Poloxamer 407) or Pluronics, Synperonics In some embodiments, the composition further comprises a pharmaceutically acceptable solvent. In some embodiments, the fatty acid is myristoleic acid, palmitoleic acid, sapienic acid, oleic acid, elaidic acid, geranic acid, vaccenic acid, linoleic acid, linoelaidic acid, alinolenic acid, arachidonic acid, eicosapentaenoic acid, erucic acid, docosahexaenoic acid, propionic acid, butyric acid, valeric acid, hexanoic acid, enanthic acid, caprylic acid, pelargonic acid, capric acid, undecylic acid, lauric acid, tridecyclic acid, myristic acid, pentadecylic acid, palmitic acid, margaric acid, stearic acid, nonadecylic acid, arachidic acid, heneicosylic acid, behenic acid, tricosylic acid, lignoceric acid, pentacosylic acid, cerotic acid, heptacosylic acid, montanic acid, nonacosylic acid, melissic acid, henatriacontylic acid, lacceroic acid, psyllic acid, geddic acid, ceroplastic acid, or hexatriacontylic acid. In some embodiments, the combination of a gelling agent and a pharmaceutically acceptable solvent is referred to as a gel base. In some embodiments, a gel base is created prior to the addition of an ionic liquid to the gel base. In some embodiments, the ionic liquid is added into the gel base. In some embodiments, the gel base is added into the ionic liquid. In some embodiments, the gel base comprises water and a gelling agent. In some embodiments, the gel base comprises di-isopropyl adipate and a gelling agent. In some embodiments, the gel base comprises PEG400 and a gelling agent. In some embodiments, the gel base comprises propylene glycol and a gelling agent. In some embodiments, the gelling agent is HEC, HPC, or HPMC. In some embodiments, the gel base comprises ethanol and a gelling agent. In some embodiments, the gel base further comprises glycerin, propylene glycol, ethanol, or a combination thereof. In some embodiments, the transdermal composition comprises of cyclosporine in the concentration range of about 1 to about 10 % w / v. In some embodiments of any of the aspects, the concentration of cyclosporine of about 1 to about 5 % w / v. In some embodiments, the ionic liquid comprises of choline in the concentration range of about 1 to about 50 % w / v. In some embodiments of any of the aspects, the concentration of choline of about 5 to about 20 % w / v. In some embodiments of any of the aspects, the concentration of choline of about 8 to about 10 % w / v. In some embodiments, the ionic liquid comprises of geranic acid in the concentration range of about 1 to about 50 % w / v. In some embodiments of any of the aspects, the concentration of geranic acid of about 10 to about 30 % w / v. In some embodiments of any of the aspects, the concentration of geranic acid of about 15 to about 25 % w / v. In some embodiments, the transdermal composition comprises of pluronic gel in the concentration range of about 1 to about 50 % w / v. In some embodiments of any of the aspects, the concentration of pluronic gel of about 2 to about 25 % w / v. In some embodiments, the transdermal composition comprises of PEG400 in the concentration range of about 1 to about 100 % w / v. In some embodiments of any of the aspects, the concentration of PEG400 of about 25 to about 75 % w / v. In some embodiments, the transdermal composition comprises of choline and geranic acid (CAGE) ionic liquids 1:1 ratio to about 10:1 mixed with pluronic gel and PEG400 to prepare the formulation of cyclosporine A (CsA). In some embodiments, the transdermal composition comprises of choline and geranic acid (CAGE) ionic liquids in 2:1 ratio mixed with Pluronic gel (22.7 % w / v) and PEG400 (45%) to prepare the formulation of cyclosporine A (CsA). In some embodiments, the composition is clear. In some embodiments, the composition is turbid. In some embodiments, the composition is opaque. In some embodiments, the composition is a colloidal system. In some embodiments, the composition is formulated for transdermal administration. In some embodiments, the composition is formulated as liquids, films, depots, gel, lotion, cream, ointment, solution, or as patches. In some embodiments, the composition the composition is delivered to the skin surface by a drug delivery device containing a reservoir for holding it. In a preferred embodiment, the reservoir may also contain one or more drug(s). In some embodiment, the composition may be contained within a drug delivery device. A variety of different devices having a variety of different geometries and structures may be used. For example, the device may be a multicompartment device, which also contains the composition. EXAMPLESThe present invention is represented below by the help of representative examples. The examples do not limit the scope of the present invention. Although the invention has been described with reference to specific embodiments, this description is not meant to be construed in a limiting sense. Various modifications of the disclosed embodiments, as well as alternate embodiments of the invention, will become apparent to persons skilled in the art upon reference to the description of the invention. It is therefore, contemplated that such modifications can be made without departing from the spirit or scope of the present invention as defined. MATERIALS AND METHODS Materials Cyclosporine A (pharmaceutical secondary standard, > 97.0% pure) was purchased from Tokyo Chemical Industry Co., Ltd. (Japan). Oleic acid (99+%, analytical reagent grade) was purchased from SD Fine-Chemical Limited (Hyderabad, India). Palmitic acid (99+%, analytical reagent grade) was purchased from Sisco Research Laboratories Pvt. Ltd (Hyderabad, India). Choline bicarbonate (technical grade, 80% in H2O), geranic acid (technical grade, 85% in H2O), acetonitrile, Kolliphor P407 oxyethylene 71.5 - 74.9 % (Lutrol F127 or Poloxamer 407) and orthophosphoric acid were purchased from SigmaAldrich Chemical Company (Bengaluru, India). Milli-Q (Millipore Inc., USA) water was used for all the experiments. Preparation of CAGE and chemical enhancers with cyclosporine A Two equivalents of geranic acid (4.01 ml; 85 wt%) was added to one equivalent of choline bicarbonate (1.76 ml; 80 wt%) in an opened round bottom flask. The mixture was stirred at room temperature (RT) until no more carbon dioxide (CO2) evolved. cyclosporine A (58.44mg) was added to the mixture to prepare 10 mg / ml cyclosporine A solution. The flask was kept for further stirring (200 rpm; 1h) at room temperature to form clear solution. To prepare OA and PA mixtures of cyclosporine A, 0.25% w / v was optimized based on their solubility profile in addition to cyclosporine A in the mixture of phosphate buffered saline (PBS; pH 7.4) and isopropyl alcohol (IPA) in 65: 35% ratio. These solutions were then used for skin permeation studies. Solubility studies The saturation solubility of cyclosporine A was determined in the vehicles, PBS + ethanol mixture; IPA; CAGE; and mixture of polyethylene glycol 400 (PEG) and CAGE in the presence of OA and PA. An excess of cyclosporine A was taken in a 5ml centrifuge tube, with or without the addition of enhancers. The dispersions were incubated in a shaker maintained at 37°C for 7 days. The samples were withdrawn at periodic intervals and centrifuged at 10,000 rpm for 10 min.
[41] . The supernatant containing cyclosporine A was diluted with acetonitrile. The samples were analyzed using a RP-HPLC method. The cyclosporine A concentration was calculated using a standard curve generated in acetonitrile (0.1 - 50 μg / ml; r 2 = 0.9995). Preparation of CAGE-Pluronic gel The gel formulation was optimized by varying poloxamer 407 concentrations (2.1 - 22.7 % w / v) (Table 1). Poloxamer P407was mixed with PEG400 at 55-60°C temperature under continuous stirring for 30 min. In a separate beaker, 5.8 ml of CAGE and cyclosporine A (58.44 mg) were mixed at room temperature for 1h. The CAGE-cyclosporine A mixture was added to Pluronic-gel base at 55°C, under continuous stirring for 45 min. Tea tree oil was added to mask the tingent smell of CAGE. The gel was stored at 2-8°C until further use. Table 1. Formulation trials for different Pluronic gel (PLG) containing cyclosporine (CsA)PEG-400- Polyethylene glycol; CB- Choline bicarbonate; GA- Geranic acid; CsA- cyclosporine A. Both CB and GA are used as Ionic liquids in the ratio 1:2 M. Tea tree oil is used as fragrance.Characterization of cyclosporine A loaded CAGE-Pluronic gel The gels were visually evaluated for color, clarity and phase separation. pH was measured using digital pH meter (Eutech Instruments, ThermoScientific, Hyderabad, India). Rheological analysis was performed using a thermostatically controlled modulated compact rheometer (Anton Par MCR 302, Austria). The parallel-plate (PP) geometry with an inset I-PP 50 / SS mm diameter and 1° angle was used. Probe PP25 was attached to the upper coupling shaft with loading position, target mode and minimum gap of 60mm, 5mm and 0.5mm, respectively. The samples were analyzed selecting the measuring system (D - PP 25 SN000000) and measuring cell (P-PTD 200 + H - PTD120 SN82735654 - 82718190). Temperature sweep test was conducted at a heating rate of 2°C / min within the temperature range of 25 - 60°C.The viscosity was measured by varying shear rate (0.01 s -1 - 500 s -1) at 25°C temperature. The data was analyzed using Ostwald - de Waele or power law, calculated using Eq. (1): σ = K.(γ) n (1) where σ is shear stress at break (Pa), K is consistency index of fluid at a shear rate of 1.s -1, (Pa.s n), γ is shear rate (1.s -1), and nis power law index (dimensionless). Taking log on both the sides, log σ = log k + n log γ (2) shear stress (dynes / cm 2) = viscosity (centipoise) x shear rate (1 / s) The power law model gives n<1, for a shear thinning (pseudo-plastic) fluid, n>1 and for a shear thickening(dilatant) fluid n= 1 for Newtonian samples. 1H NMR spectroscopic analysis (Avance NEO 400 MHz, Bruker, USA) was performed for neat cyclosporine A, choline bicarbonate, geranic acid, blank and cyclosporine A CAGEgel after dissolving in deuterated acetic acid. The gel samples were heated to 55°C for its conversion to sol state. The spectra were analysed using Top Spin 4.0.3 software. FTIR spectroscopic analysis (Jasco FT / IR - 4200, Japan) was performed for neat cyclosporine A, Pluronic F127, blank (CAGE-P) and cyclosporine A CAGE-gel (CsA_CAGE-P). For solid samples, the sample (1-2 mg) was mixed with an equal amount of KBr and compressed using a hydraulic press to prepare a pellet. For liquid samples, the sample (20μl) was drop-casted on the KBr pellet and was dried for 5 min. The pellets were mounted on the dynamic reflectance sample holder to record % transmittance within the range of 4000-400 cm -1 wave number. Powder X-ray diffraction analysis (PXRD, Ultima IV, Rigaku, Japan) was performed to determine the presence of crystalline or amorphous regions in the neat cyclosporine A, Pluronic F127, CAGE-P andCsA-CAGE-P gel. The samples were placed on the sample holder and scanned between 5 and 50° 2θ using a copper Kα radiation source having 1.542 Å wavelength and 1 mm slits. The test was carried out at a 1° / min scan speed and step size of 0.01° at ambient temperature. Differential scanning calorimetry (DSC) was performed using DTG-60 Simultaneous DTA-TG apparatus (Shimadzu, Japan). The samples, neat cyclosporine A, Pluronic F127, CAGE-P and CsA-CAGE-P gel, weighing 5-10 mg were placed in the standard aluminum pans. Thermograms were recorded from 30 to 250°C at a heating rate of 5°C / min. The swelling index of both CAGE-P and CsA-CAGE-P gel was measured in glass petriplates, by suspending 0.3 g of gel in 5ml of phosphate buffered saline (PBS, pH 7.4) at 37°C. The weight of the gel was noted before (initial weight) and at different time intervals (final weight). The swelling index was calculated using Eq. (2). [Equation 3]Scanning electron microscopy (SEM, Apreo LoVac, FEI, USA) was performed to acquire high-resolution micrographs of CsA-CAGE-P gel. xT Microscope Control software was used to capture SEM images at a magnification of 500x and 2000x. The samples were prepared by sputter coating the patches to a thickness of 10 μm with gold. The images were captured at a resolution of 1 nm and an accelerating voltage of 20 kV with a working distance adjusted to 10 mm. Goniometer (Attension Theta Flex, Biolin Scientific, UK) with a high-resolution camera was used to determine the contact angle of gel placed on excised porcine ear skin. Sessile drop method was used, where the automated pipette placed 10 μl of gel onto the surface area (0.64 cm 2) of the skin. One Attension software was used to measure the contact angle at 0, 20, 40 and 60 s. To determine the amount of cyclosporine A loaded in CAGE-P gel, samples (0.05 g) were weighed, mixed with 10 ml of acetonitrile: water (95:5 v / v) and sonicated for 20 min. Samples of 1 ml were filtered (nylon syringe filter, 0.22-μm pore) and analyzed by HPLC for determining cyclosporine A concentration as described below. HPLC method to analyze cyclosporine A Reverse phase-HPLC (LC20-AD, Shimadzu Inc. Japan) was used to quantify cyclosporine A in samples from in vitro drug release studies and ex vivo skin permeation studies. Chromatographic separation of components within samples was achieved using Luna C8 column (150 x 4.6 mm) (Phenomenex Inc. USA) with pore size 100Å. cyclosporine A was eluted using mobile phase comprised of 95% v / v acetonitrile and 1% v / v orthophosphoric acid in deionized water. Mobile phase was pumped at a flow rate of 0.5ml / min and was detected at 210nm wavelength using UV detector. The standard samples were prepared in PBS (pH 7.4) methanol mixture (65: 35) within the concentration range of 0.5 - 100 μg / ml. The regression equation and correlation coefficient obtained from regression analysis was y = 33725x - 41034 and R 2 = 0.9999, respectively. The retention time for cyclosporine A elution was found to be 3.2 min. In vitro drug release study In vitro release studies were performed using Franz diffusion cell apparatus (PermeGear, Inc., PA). Dialysis membrane (molecular weight cut off, 2kDa; Himedia, India) was placed between the donor and receptor compartments of a diffusion cell. PBS and methanol mixture (65: 35%) was used as the receptor medium and the temperature was maintained at 37°C using heated water circulator. The donor compartment was loaded with 0.2% of CsA containing CAGE or CAGE-P gel formulation. Samples (300 μl) were withdrawn from the sampling port at predetermined time intervals 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36 and 48 h and replaced with fresh media. Samples were analyzed using HPLC method described above. The drug release profiles for were modelled using the following equations: 1. Zero-order kinetics; F = K0t (4) where F is the fraction of drug released at time t and K0 is the zero-order release constant. 2. First-order kinetics; In (1-F) = K1t (5) where K1 is the first-order release constant. 3. Higuchi model; F = -K2t 1 / 2 (6) where K2 is the Higuchi constant. 4. Korsmeyer-Peppas Model; (Mt / M∞) = K3t n (6) where (Mt / M∞) is the fraction of drug released at time t, K3 is the release rate constant, and n is the release exponent. The different release mechanisms were characterized using the calculated n value. When n < 0.5, the diffusion mechanism is quasi-Fickian, n = 0.5 is Fickian diffusion, 0.45 <n < 1 refers to non-Fickian diffusion, n = 1 is case-II transport, and n > 1 refers to super case-II transport
[42] . Preparation of skin samples Freshly excised porcine ears were procured from the local abattoir. Ears were washed under tap water, and hair on the dorsal side was removed using a hair clipper. The dorsal skin was excised from the underlying cartilage with scalpel and forceps. Fat adhering on the dermis side was carefully removed using a blunt scalpel and the skin was observed for any visible damage. The skin samples were wrapped in Parafilm and aluminum foil and stored at -20°C for a maximum period of 3 months. Measurement of TEWL and Skin Resistance The integrity of the skin samples was determined by measuring transepidermal water loss (TEWL) and trans-epidermal electrical resistance (TEER). TEWL (gm / m 2 / h) was measured by placing vapometer (Delfin Technologies, Inc. Finland) on the donor chamber in a Franz diffusion cell. The room temperature was maintained between 22 and 26°C and the relative humidity was between 46 and 50%. The skin samples with TEWL values < 10 gm / m 2 / h were only used in the study. For measuring skin electrical resistance, a direct current of 0.3 mA / cm 2 (I) was applied using a constant power supply unit, where cathode was placed in the receptor chamber containing PBS (pH 7.4) -methanol mixture through the sampling port and the anode was placed in the donor chamber containing 0.2ml of PBS solution. The potential difference (V) across the skin was measured using a multimeter (Fluke 189, USA). The skin resistance (R) was calculated using Ohm's law (V = IR). The skin samples with electrical resistance >10kΩ / cm 2 were used for further studies. Ex vivo skin permeation studies Cyclosporine A permeation across the intact porcine ear skin was performed using a Franz diffusion cell apparatus. The skin sample was thawed at room temperature and equilibrated on Franz diffusion cell for 6 h. Micrometer was used to measure the skin thickness. and the thickness was 0.35 - 0.45 mm. The skin samples were sandwiched between the donor and receptor chambers of diffusion cell with stratum corneum (SC) facing the donor chamber. The effective diffusional area available was 0.64 cm 2. The receptor chamber was filled with 5 ml of PBS-methanol mixture (65: 35%), that was stirred continuously using a magnetic bar at 600 rpm. The receptor medium was maintained at 37°C by a heated water circulator. The donor chamber was charged with 0.2 ml of different formulations. The control formulation included 10 mg / ml cyclosporine A solution (dissolved in PBS-ethanol; 65: 35%). Palmitic acid, oleic acid, CAGE or CsA-CAGE-P gel were used to study the influence of chemical enhancers on skin permeation of cyclosporine A. The skin samples were co-treated with a mixture of cyclosporine A (10 mg / ml) - CAGE (1:2 molar ratio) or cyclosporine A (10 mg / ml) - oleic acid (0.25% v / v) and palmitic acid (0.25% v / v) for 48 h. Similarly for CAGE-P gel, saturated solution of cyclosporine A (4%) in (96%w / v) gel base was applied on the intact skin for 48 h. This was compared with CsA-CAGE-gel (1%), prepared in (99%w / v) gel base. The donor chamber was sealed with a two-fold Parafilm to prevent evaporation. Samples (0.3 ml) were withdrawn from the receptor chamber at pre-determined time points throughout 48 h and were replenished with fresh media, maintained at 37°C. The samples were analyzed for cyclosporine A concentration using the RP-HPLC method described above. Skin permeation parameters were calculated from the cumulative amount of cyclosporine A permeated per unit area versus time profile. The flux (J) was calculated from the slope of the linear portion of the curve, and the lag time (tlag) was calculated by extrapolating the linear portion of the curve onto the time axis. The linear portion for most of the permeation profiles was obtained between the time points of 2 and 48 h. The correlation coefficient of linear portion of the curve was 0.97-0.99. The permeability coefficient (Kp) and diffusion coefficient (D) of cyclosporine A across porcine skin were calculated using the following equations. Permeability coefficient (Kp) = Flux (F) / Concentration of CsA (C) (7) Diffusion coefficient (D) = Skin thickness (h2) / 6 x lag time (8) Enhancement ratio (ER) was calculated by dividing the Kp of cyclosporine A in the presence of CAGE / permeation enhancers with the Kp of cyclosporine A in the absence of CAGE / permeation enhancers. Determination of cyclosporine A within skin samples After treatment with respective formulations, the skin samples were analyzed for disposition of cyclosporine A. The surface of the skin samples was washed with 3ml of PBS. Tape-stripping was performed to remove SC from the intact skin samples. The treated skin area was sequentially stripped 5 times using scotch book tape, which were pooled and quantified for cyclosporine A. The stripped tapes were incubated overnight at 4°C in a 1.5ml microcentrifuge tube containing 1ml of PBS: methanol mixture to extract cyclosporine A. The remaining viable skin was cut into small pieces and homogenized using tissue homogenizer (IKA T10 basic; ULTRA - TURRAX ). Acetonitrile (500μl) was added to the tissue sample and sonicated for 45 min. Then the samples were centrifuged at 10,000rpm for 20 min at 4°C temperature. The supernatant was collected and analyzed for cyclosporine A using the RP-HPLC method described above. The percent recovery was calculated by comparing the peak areas of cyclosporine A extracted from the skin samples with equivalent known amount of cyclosporine A. Studies to determine the mechanism of action of chemical enhancers or CAGE-P gel on skin permeation of cyclosporine A For FTIR studies, the excised porcine ear skin was maintained at 60°C in a water bath for 90s to remove SC from the viable skin. The excised SC and viable skin samples were treated with 0.2 ml of CAGE, PA (0.25% w / v) or OA (0.25% w / v) or CAGE-P gel (0.2% w / w) at 37 °C for 12, 24 and 48 h. The samples were washed with 3ml of PBS and dried for 1h at room temperature (RT). The dried samples were cut into small pieces and mixed uniformly with potassium bromide (KBr) in the ratio 1:100. The sample mixture was compressed into a pellet using a hydraulic press by applying 40 kN force. The SC sample treated with PBS and ethanol (65: 35%) mixture for similar time points was used as the control. The spectra were recorded using infrared spectrophotometer (Jasco FT / IR-4200, Japan) for each 1.5 cm x 1.5 cm SC piece, by mounting the sample on the dynamic reflectance sample holder within the range 4000-400 cm -1 wavenumber and a resolution of 4 cm -1. Thermal analysis was performed by taking 2-5 mg of SC in standard aluminum pan. The samples were treated with 0.2 ml of CAGE variant (1: 2), PA (0.25% w / v) or OA (0.25% w / v) or CAGE-P gel (0.2% w / w) for 12, 24 and 48 h time points. The samples treated with PBS and ethanol (65: 35%) mixture were considered as the control. Thermal analysis was performed using DTG-60 Simultaneous DTA-TG apparatus (Shimadzu, Japan). All the samples were analyzed between 28 and 200°C temperature at 2°C / min heating rate and under 40 ml / min nitrogen flow rate. The transition temperatures and their corresponding enthalpy changes were determined. Scanning electron microscopy (SEM; Apreo LoVac, FEI, USA) was used to visualize high-resolution micrographs of SC samples treated with 0.2 ml of CAGE variant (1: 2), PA (0.25% w / v) or OA (0.25% w / v) or CAGE-P gel (0.2% w / w). xT Microscope Control software was used to capture SEM images with a magnification of 500Xto2000X. The treated SC samples were sputter coated to a thickness of 10 μm with gold. The images were captured at a resolution of 1 nm and an accelerating voltage of 20 kV with a working distance adjusted to 10 mm. Pharmacokinetic studies Preparation and analysis of cyclosporine A standards in rat plasma The cyclosporine A stock solution was prepared by dissolving 5 mg in 5 ml acetonitrile. The plasma collected from rat was added to the cyclosporine A solutions to achieve standard concentrations in the range 0.0001-18.75 μg / ml. Then, 300 μl of acetonitrile was added to each plasma sample and vortexed for 15 min. The mixture was centrifuged at 11000 rpm for 15 min at 4°C. The supernatant was then transferred to a clean 2 ml HPLC glass vial and was used for the quantification of cyclosporine A. The RP-HPLC method followed for analyzing cyclosporine A in rat plasma was modified from the method discussed above. The flow rate was increased to 0.8ml / min with the cyclosporine A eluted at 1.87 min and detected at 210 nm wavelength. The concentration was calculated against a standard plasma calibration curve obtained for concentration range 0.00037-18.75 μg / ml with R 2 = 0.9985 and regression equation y = 45415x + 253903. The male Sprague Dawley rats aged 8-10 weeks with the average weight of 180 ± 20 g were used in this study. The experimental protocol was approved by the Institutional Animal Ethics Committee (IAEC) of BITS Pilani, Hyderabad Campus (HYD / IAEC / 2021 / 09). The rats were divided into four groups having four animals in each. The animals were kept in separate cages and were anesthetized using 5% isoflurane and 21% oxygen mixture at a flow rate of 1 L / min (EZ animal systems, Canada). The hair on the dorsal side was clipped using a hair clipper without causing injury. cyclosporine A formulations were applied on an area of 3 cm 2. The formulations included cyclosporine A (40 mg) in 1 ml of PBS-ethanol mixture (0.65+0.35 ml, control group), cyclosporine A (40 mg) + PA (2.5 mg) solubilized in 1 ml PBS + IPA (0.65+0.35 ml) mixture, cyclosporine A (40 mg) in choline bicarbonate + geranic acid (0.31+0.69 ml) mixture, cyclosporine A (40 mg) in choline bicarbonate + geranic acid (0.31+0.69 ml) mixture dispersed in 1g of pluronic gel base. The formulations were gently spread on the rat skin using a micropipette tip. Later, blood samples (~250 μl) were collected by puncturing retro-orbital plexus in plastic centrifuge tubes containing 20 μl of 2% disodium ethylene diammonium tetracetic acid salt at pre-defined time points of 0.5, 1, 2, 4, 8, 12, 24, 36 and 48 h. The blood samples were centrifuged at 7500 rpm for 15 min at 4°C and the separated plasma samples were quantified for cyclosporine A using the HPLC method described above. Measurement of TEWL and LDF in Sprague Dawley rats TEWL and laser Doppler flow rate (LDF) were measured before and after 2 h of application of neat cyclosporine A, cyclosporine A in combination with PA or CAGE in to understand the change in skin integrity and irritation potential. TEWL was measured by placing the vapometer probe on the dorsal skin surface of rat under gaseous anaesthesia. TEWL was measured in a ventilated room having controlled temperature between 25 and 28°C and relative humidity of 38-40%. LDF was measured using Laser Doppler Perfusion and Temperature Monitor (moorVMS - LDF, UK). The fiber optic probe containing a diode laser was held gently on the skin to avoid vascular compression
[43] . Instrument was allowed to warm up and stabilize for 15 min before recoding the LDF values. The flow rate was recorded for 30 s under anaesthesia. The cutaneous irritation index was also measured as the enhancement of cutaneous blood flow, before and after 2 h application of formulations. The ratio was calculated dividing LDFtest formulations by LDFcontrol formulation
[44] . Efficacy studies Imiquimod induced psoriatic plaque model Imiquimod (IMQ) induced psoriatic plaque model was developed to evaluate the efficacy of CsA-CAGE-Pgel. Male SD rats of age 8 to10 week weighing180-220 g were used for the study. Animals were housed under controlled environmental conditions (temperature 23±1 °C, humidity 50 ±5%, and 12 h light / dark cycles) with food and water ad libitum. The rats were divided into four groups having four animals in each group. Group 1 was the control which had no disease induced. Group 2 was IMQ -applied induced psoriasis and Group 3 was without any treatment for the IMQ- induced psoriatic condition. Group 4 and Group 5 was the treatment group with the topical application of CsA-CAGE-P gel (10 mg / kg / day) and i.v. injection of CsA, of similar CsA concentration as that of CsA-CAGEP gel. All the animals were shaved on their dorsal side, prior to 24 h. Except control group, for all the other remaining groups, 62.5 mg of commercially available IMQ cream (5% w / w) was applied on the shaved back for 8 consecutive days. The animals (treatment groups) were treated with respective formulations from 9 thday of the study and continued till 16 thday. TEWL, LDF, behavioral changes, changes in body weight, food and water intake were recorded and captured, every day for all groups. Measurement of rat body temperature by infrared thermal image The body temperature of rat in each group was measured by holding the infrared thermal gun (Fluke, USA) on the inflamed area, in anesthetized animals. The thermal gun was placed at 1mdistance from the inflamed area, with fixed parameters such as (body emissivity-0.98, relative humidity-50% and atmospheric temperature-24°C). The thermal images were captured and analyzed using FLIR thermal studio software version 1.9.10 (Teledyne FLIR LLC, US) PASI scoring To score the severity of the inflammation of the skin, an objective scoring system was developed based on the clinical Psoriasis Area and Severity Index (PASI). It included the visual examination of the following three parameters: erythema (redness), induration (thickness) and desquamation (scale) on the back skin of each rat. All animals were assessed for the severity of the psoriasis-like skin condition on days 0, 2, 4, 8, 10, 12, 14 and 16, using 2 elements of the PASI, to assign a score of 0 - 4 (0, none; 1, mild; 2, moderate; 3, severe; 4, very severe) for each of the parameters. The evaluation was done independently by 5 researchers for each parameter, and the mean value ± SD (n = 4) was then calculated. These scores were plotted with time point (days) on x-axis and PASI score (0-4) on y-axis. Omitting evaluation of induration by PASI, thickness of a skinfold on the back was measured by using a vernier calliper (Baker, India)
[45] . Animals were sacrificed by cervical dislocation and the dorsal skin was excised, collected, and stored at - 80°C for further use. The spleen weight was measured and is reported as spleen to body weight ratio as mean ± SD (n = 4) for each animal in each group. Histological analysis The skin sample was embedded in an optimum cutting temperature (OCT; PolyFreeze, Polysciences, Inc, Warrington) compound by placing at - 80°C for 12h. The skin sample was cut into thin (5μm) sections using a cryostat (CM1520, Leica Biosystems, Germany). Haematoxylin and eosin (HE) staining was performed for histological evaluation. Microscopic images of the sections were acquired using an optical microscope (Olympus IX53, Olympus Corporation, Japan). Blinded to treatment group, epidermal thickness, was an accepted endpoint for measuring psoriasis severity. The thickness was measured as an average of 10-15 random measurements of the distance from the stratum granulosum to the stratum basale, using Image J software, version 4.0. Ex-vivo skin permeation studies across rat skin Permeation studies of cyclosporine A across the healthy, psoriatic skin or psoriatic skin with or without treatment with CsA-CAGE-P gel or conventional CsA i.v. formulation, was performed using a Franz diffusion cell apparatus with an effective contact area of 0.64 cm 2. After the psoriasis was successfully induced by IMQ as described in 3.5.1. section, the rats were sacrificed by cervical dislocation. The dorsal skin was immediately excised, and the subcutaneous tissues were surgically removed. The skin was sandwiched between the donor and receptor cells with SC facing upward into the donor. Skin temperature was maintained at 32°C±1°C throughout the experiment with a circulating water bath and stirred at 600 rpm. After equilibration of 6 h, TEWL and TEER was measured. Intact skin samples were applied with 0.2 ml of saturated CsA-CAGE-P gel (4%) formulation for 48 h. Samples (0.3 ml) were withdrawn from the receptor chamber at pre-determined time points throughout 48 h and were replenished with fresh PBS-methanol solution (65: 35%), maintained at 37°C. The samples were analyzed for cyclosporine A concentration using the RP-HPLC method described in the section 2.5. Similarly, the skin permeation parameters were calculated. After 48 h permeation, the diffusion cells were dismantled, the residual formulations on the treated skin were carefully removed, and the skin was cut into pieces. 500μl of acetonitrile was added to the skin pieces for extracting cyclosporine A retained in the skin. The extraction was performed by sonicating for 45 min following centrifuging for 20 min at 10,000 rpm. The supernatant was collected and analyzed for cyclosporine A using the RP-HPLC method. Statistical Analysis All the experiments were repeated at least four-times. The results are presented as mean ± standard deviation. The differences between various treatment groups were compared using one-way ANOVA or unpaired t-test (GraphPad Prism, 5.03 version), where the difference was significant when p< 0.05. Results Characterization of cyclosporine A loaded CAGE-Pluronic gel For the optimized CsA-CAGE-P gel, before incorporation of ionic liquids, was observed to be white-opaque. After ionic liquids incorporation, the gel formulation became slightly yellowish, because of the inherent yellow colour of the ionic liquids itself. Neither particulate materials nor any phase separation was observed on storage at room temperature (25°C / 60% RH) for 6 months. The physiological pH of the stratum corneum is 4.1 - 5.8
[46] . The measured pH for both the cyclosporine A-CsA-CAGE-P and CAGEP gel was found to be 5.2 ± 0.61 and 4.83 ± 0.21, respectively. The rheological parameters such as elastic (G') and viscous (G") moduli, as well as complex viscosity (η), were determined for all gel formulations. Additionally, the gel-sol transition temperature was also obtained to predict the possible influence of both cyclosporine A and Pluronic (PL) incorporation on gel composition and structural organization. To this context, gel formulations were also analyzed for the varying concentrations of PL used for the fabrication of the gels. The transition temperature for the gels was found to increase with increase in PL concentrations. For Pluronic - 188 gel formulation (4.6% w / v), the transition temperature (gel to sol) was found to be 39 ± 2.8°C. However, this was not the case for Pluronic - 127 gel formulation, where the gel to sol transition temperature was found to be 42.5 ± 2.3°C for PL concentration (4.6% w / v). For the optimized CsA-CAGE-P gel formulation, transition temperature was found to be 47.8 ± 1.6°C for PL concentration (22.7% w / v) (Figure 2a). The temperature sweep analysis revealed viscoelastic gel-like properties (Storage modulus; G' > loss modulus; G"), when measured in the temperature range 25 - 60°C. The G' and G" parameters increased with increase in the PL concentrations (4.6 % - 22.7% w / v), resulting in the formation of a more structured network (Figure 2b, c). At 25°C, G' for CsA-CAGE-P and CAGE-P gel formulation was 447870 ± 6717 Pa and 295277 ± 3987 Pa, respectively. G" for CsACAGE-P and CAGE-P gel formulation was 56221 ± 99 Pa and 48561 ± 72 Pa. However, G' and G" for both CsA-CAGE-P and CAGE-P gel formulation reduced significantly (p < 0.05) at 48°C (Figure 2d). Rheological studies were also carried out to measure changes in the viscosity with change in temperature and shear rate. Figure 2a shows the viscosity profile for CsA-CAGE-P gel and formulation at 25°C, which was found to be 71031 ± 121 Pa. s. However, the viscosity decreased significantly at (p < 0.05) by ~87 - fold for CsA-CAGE-P gel formulation at 48°C. Figure 2d shows the viscosity as a function of varying shear rate for CsA-CAGE-P gel formulation. The viscosity for CsA-CAGE-P gel formulation at 25°C was in the range (1.62 x 10 8 - 2235mPa.s) with a varying shear rate from (0.01 - 500 [1 / s]). Figure 3 shows the proton NMR spectra ( 1H-NMR) for cyclosporine A, CsA-CAGE-P gel, CAGE-P gel, geranic acid and choline bicarbonate, arranged from bottom to top. Resonance of NH protons between 7 and 12ppm, the α-protons as well as the olefinic protons between 4.5 and 6 ppm, the N-methyl groups between 2.6 and 3.8 ppm, the Cmethyl groups between 0.6 and 1.8 ppm, and the aliphatic groups in the range of 1.1-2.7 ppm was observed for cyclosporine A. The appearance of the same signals and up-field chemical shift in the NH protons from 11.4 to 11.1 ppm, with (∆δ = 0.3) confirms the loading of cyclosporine A in Pluronic gel. However, the interaction of exchangeable proton (- OH) with acidic groups of ionic liquids or pluronic (PPO or PEO) block was confirmed by the appearance and down-field chemical shift of peak at 10.9 ppm for blank gel formulation. Presence of intense singlet peak of carboxylic (-COOH) groups at 11.5 ppm for geranic acid and appearance of aldehydic proton (- CHO) at 9.7 ppm for choline bicarbonate was observed. The X-ray diffraction patterns of neat cyclosporine A, PF - 127, CAGE-P and CsACAGE-P gel is presented in Figure 4a. The X-ray diffraction pattern showed crystalline nature of cyclosporine A with major peaks at 2θ values of 6.78°, 9.12°, 15.06°, and 16.80°. The X-ray diffractograms of pure PF - 127 showed the distinct crystalline peaks at 2θ values of 18.89° and 23.09°. The CAGE-P and CsA-CAGE-P gel showed peaks with reduced intensity at 2θ values of 18.89° band 23.09°, similar to PF - 127. However, no characteristic diffraction peaks of cyclosporine A were observed in CsA-CAGE-P gel which confirms the amorphous nature and homogeneous dispersion of drug within the gel matrix. Figure 4b shows the representative FTIR spectra of the neat cyclosporine A, PF - 127, CAGE-P and CsA-CAGE-P gel formulations. The spectra were arranged from bottom to top. The characteristic peaks of cyclosporine A were found at 1629.6 cm -1 (carbonyl group) and 2960.2 cm -1 (stretching vibration of aliphatic C-H bonds). The appearance of peaks in the wavenumber range (2969 - 2578 cm-1) indicates strong broad, O - H stretching for geranic acid. The peaks at 1691 and 1641 cm -1 confirms C = O stretching. The absorption band intensity at 1433 cm -1, 1378 cm -1 and 706 cm -1 relates strong and medium C - H bending. Peaks at 865 cm -1 and 824 cm -1 indicates strong C = C bending. The absorption band intensity in the region 2884 cm -1, corresponded to the stretching vibrations of the CH-groups in Pluronic molecule. The absorption peak at 1343 cm -1 is related to (in - plane O - H bending). The broad peak in the region of 1100- 1070 cm -1 corresponded to the stretching vibrations of C - O groups of Pluronic F127. Stretching vibrations of bonds such as (C - O - C stretch) at 1278 and 1249 cm -1 and (C - O stretch) at 1097 cm -1 were also observed. The presence and slight bathochromic shift in the characteristic peak to 2989.3 cm -1 and hypsochromic shift to 1189.2 cm -1, revealed the loading of cyclosporine A in CAGE-P gel matrix. However, the presence of broader peaks at (3100 and 3600 cm -1) in both the CAGE-P and CsA-CAGE-P gel, confirms immense intermolecular hydrogen bonding. Representative DSC thermograms for neat cyclosporine A, PF - 127, CAGE-P and CsACAGE-P gel are shown in Figure 4c. cyclosporine A and PF - 127 showed an endothermic transition at 132.3ºC and 57.3ºC temperature, indicating crystalline nature. The appearance of endothermic peak at 41.4ºC and 40ºC temperature for both CAGE-P and CsA-CAGE-P gel is due to the presence of PEG - 400 in gel formulation, which is evident from the literature
[47] . The appearance of endothermic peaks from (160 - 200ºC) temperature in both CAGE-P and CsA-CAGE-P gel, is attributed to the interaction of ionic liquids in the gel base. However, the disappearance of characteristic melting endotherm in CsA-CAGE-P gel formulation, indicates that cyclosporine A was converted to amorphous state and might have been completely entrapped in PF - 127 in molecular level [47, 48]. To determine the amount of solvent uptake by the gel, the swelling index was measured in phosphate buffered saline (PBS; pH 7.4) at 37°C. Figure 4d shows the increase in percentage swelling index of the CsA-CAGE-P gel (26.2 ± 3) with the increase in incubation time from 0 to 16 h. However, the CAGE-P gel disintegrated within 12 h with significant decrease (p < 0.05) in percentage swelling index (19.7 ± 4). For morphological characterization, FESEM images of CsA-CAGE-P gel formulation is shown in Figure 5b. The image revealed the entangled fibrillar structure for this gel system. The formation of uniform supramolecular aggregates (i.e., entangled fibrillar structure) suggests that the molecules are self-assembled in a hierarchical fashion to form a one-dimensional supramolecular polymer through cross-linked fibers, to form a larger network of superstructures in gels. The image also revealed sparse protuberances which may be due to the freeze-dried process before analysis [40, 49]. Figure 5c shows the contact angle measured, for the gel formulations on excised intact porcine skin with 0.64 cm 2 surface area. The results revealed super hydrophilic (< 50º) behavior of gels with contact angle measured for CsA-CAGE-P and CAGE-P gel formulation was 48 ± 2.8º and 40 ± 2.5º respectively. (Figure 5d). The cyclosporine A content for gel formulation (CsA-CAGE-P)) was found to be 96.2 ± 2.1%, confirming the homogeneous drug distribution throughout the gel formulation. In vitro drug release study The diffusion of free cyclosporine A across the dialysis membrane and release of cyclosporine A, dispersed in CAGE or Pluronic gel containing CAGE were investigated. Figure 5a shows the in vitro release profile of cyclosporine A from these formulations. The release of CsA across the dialysis membrane from CAGE was found to be 48.8 ± 1.4 %, at the end of 48 h, compared to free CsA (29.8 ± 1.8 %). In contrast, CsA-CAGE-P gel formulation showed burst release of CsA (21 ± 5.9 %) which was significant at (p < 0.05) up to 4 h, followed by sustained release (42.4 ± 1.5%) up to 48 h. Further, the release kinetics of cyclosporine A from the prepared formulations were compared in Figure 6. The kinetic model best fitted to release data was determined based on their regression coefficient (R 2), tabulated in table 2. The release mechanism was verified by Korsmeyer - Peppas model. The diffusion mechanism followed super case II transport mechanism (n = 1.7), which indicated the release was most likely driven by macromolecular chain relaxation and swelling of hydrophilic polymer chain
[50] . Table 2. In-vitro drug release kinetic models for CsA loaded CAGE- gel formulation Ex-vivo skin permeation studies using Franz diffusion cell The average thickness of porcine ear skin used for ex vivo permeation studies was found to be 380 ± 10 μm. The average TEWL and TEER for intact excised porcine ear skin was found to be 8.1 ± 1.1 g / m 2 / h and 16.2 ± 1.4 kΩ / cm 2, respectively. However, the TEWL values increased with increase in the incubation time up to 48 h, from 8.1 ± 1.1 g / m 2 / h to 18.5 ± 0.65 g / m 2 / h. In contrast, TEER values decreased from 16.2 ± 1.4 kΩ / cm 2 to 7.4 ± 1.4 kΩ / cm 2. The RP-HPLC chromatographs of cyclosporine A showed shift in retention time from 3.2 minutes to 3.4 minutes for blank skin spiked with cyclosporine A. The calibration curve for cyclosporine A was developed in skin matrix. The lower limit of quantitation (LLOQ) was found to be 1μg / ml. The percentage recovery was in the range (84 - 90 %), for the concentration ranging from 1 - 50 μg / ml. Ex - vivo skin permeation studies showed that cyclosporine A did not permeate across intact skin for up to 48 h (Figure 7a). However, the amount of cyclosporine A retained in stratum corneum, and viable skin was found to be 3121 ± 1093 μg / g and 1230 ± 291 μg / g, respectively (Figure 7b). Chemical permeation enhancers, OA and PA or ionic liquids variant (CAGE) or CAGE-P gel were used to enhance the skin permeation of cyclosporine A. Co-treatment studies were performed to understand the influence of enhancers on skin permeation of cyclosporine A. Chemical permeation enhancement or CAGE / CAGE-P gel The influence of chemical permeation enhancers on the transdermal permeation of cyclosporine A was studied using Franz diffusion cells. Permeation enhancement was studied in intact excised porcine skin model. In general, the cumulative amount of cyclosporine A permeated across the skin increased with time. Table 3 shows the permeation parameters of cyclosporine A transport across the skin. Figure 7a shows the permeation profiles of cyclosporine A in intact skin co-treated with PBS - ethanol (65: 35%) or OA (0.25% v / v) and PA (0.25% v / v) or CAGE (1 :2 molar ratio) for 48 h. The permeation profile for cyclosporine A, incorporated into Pluronic gel containing CAGE was also studied. The cumulative amount of cyclosporine A permeated across skin in 48 h was found to be 39 ± 6 μg / cm 2 with lag time of 14.8 ± 3.1 h, after cotreatment with PBS - ethanol mixture. In contrast, skin treated with OA and PA showed significant enhancement (p < 0.05) in the permeation of cyclosporine A across skin, with decrease in lag time (7.6 ± 0.2 h) for OA and (10.3 ± 2.1 h) for PA, compared with cotreatment with PBS - ethanol solution. The permeation parameters of diffusivity (0.12 ± 0.08 x 10 -3 cm 2 / h) and permeation coefficient (10 ± 1 x 10 -3 cm / h) for PA was enhanced significantly at (p < 0.05), compared to co-treatment of the skin with OA (Table 3). The cumulative amount permeated across the skin, treated with CAGE was found to be 2211 ± 14 μg / cm 2 which was significantly (p < 0.05) different compared with PBS - ethanol solution or OA or PA- treated groups. It also showed significantly (p < 0.05) greater flux, diffusivity and permeation coefficient. Therefore, CAGE was chosen to incorporate in Pluronic gel with cyclosporine A for the ease of topical application. The cumulative amount permeated, flux, diffusivity and permeation coefficient were found to be significantly (p < 0.05) greater compared with all the other groups. The lag time was found to be 2.6 ± 1.2 h. However, the cumulative amount permeated for saturated 4% cyclosporine A from CAGE gel matrix was found to be significantly (p<0.05) more up to 4 h, compared to 1% cyclosporine A-CAGE gel formulation. The lag time and flux were found to be 1.4 ± 0.9 h and 68 ± 7 μg / cm 2 / h, respectively. Figure 7b shows the amount of cyclosporine A retained within SC and viable skin after co-treatment with PBS - ethanol solution or OA or PA or CAGE in intact skin. The amount of cyclosporine A retained within SC decreased after co-treatment with PA, with increased amount in viable skin, when compared with free cyclosporine A or PBS - ethanol solution or OA treated groups. On the other hand, co-treatment with CAGE significantly (p < 0.05) enhanced the amount of cyclosporine A retained within viable skin (1861 ± 165 μg / g). However, the cyclosporine A retained within SC (1012 ± 40 μg / g) and viable skin (1211 ± 40 μg / g), decreased after co-treatment of skin with CAGE - Pluronic gel formulation. In contrast, the retention of CsA in SC and viable skin was found to be 1561 ± 101 μg / g and 1673 ± 67 μg / g for 4% CsA-CAGE-P gel formulation. Table 3. Skin permeation parameters and retention of CsA in stratum corneum (SC) and viable skin (VE) for intact skinJ, flux; Tlag, lag time; Kp, permeability coefficient; D, diffusivity and Q48, cumulative amount of CsA permeated at the end of 48 h per unit area. Thickness of the swollen intact skin ranged from 0.45 - 0.48 mm. Results are represented as mean ± SD (n = 4). 'a' represents that the cumulative amount is significantly different at (p < 0.05) compared to other CsA treated groups. 'b' and 'c' represents that the value is significantly different compared to other CsA- treated groups for stratum corneum (SC) and viable skin (VE) retention. CsA - cyclosporine A; PBS - phosphate buffered saline; PA - palmitic acid; OA - oleic acid; CAGE - choline and geranate; CsA-CAGE -P gel - CsA in Pluronic gel with ionic liquids. Mechanistic studies Table 4 shows the TEWL and TEER values of skin samples before and after treatment with PBS - ethanol solution or OA or PA or CAGE or CAGE - P gel at different time points. The TEWL value of untreated intact skin was < 10 g / m 2 / h. The treatment of skin with enhancers (ethanol;35%, OA, PA, CAGE or CAGE - P gel) significantly (p < 0.05) increased the TEWL values compared to untreated skin. The TEWL values recorded were greatest for skin samples that were treated with CAGE - P gel at the end of 12 and 48 h. The TEER values of untreated skin samples were > 12 kΩ / cm 2. The TEER values significantly (p < 0.05) decreased to ≤ 6 kΩ / cm 2 after co-treatment of skin with CAGE or CAGE - P gel at the end of 48 h compared to untreated skin. Table 4. Effect of chemical permeation enhancers or CAGE or CAGE - P gel on TEWL and TEERTEWL - transepidermal water loss and TEER - transepidermal electrical resistance. Results are represented as mean± SD (n = 4 - 6). Untreated skin was spiked with free cyclosporine A, without any enhancers. 'a' and 'b' represents that the TEWL and TEER values are significantly different at (p <0.05) compared to other treated groups for 48 h. PBS - phosphate buffered saline; PA - palmitic acid; OA - oleic acid; CAGE - choline and geranate; CAGE -P gel - Pluronic gel with ionic liquids. Figure 8a shows the FTIR spectra of intact skin before and after treatment with enhancers at different time points. The obvious shift in the peak position was not observed after treatment of SC with ethanol (35 % v / v), compared with untreated SC, suggesting negligible effects on the SC lipids. Compared with the control, the shift of asymmetric (2920 cm -1) or symmetric (2850 cm -1) C - H stretching to higher wavenumber was observed after treatment with the enhancers (OA or PA), with increase in treatment time from 2h to 12 h. However, for the SC samples incubated in CAGE or CAGE - P gel showed a prominent trend of reduced peak height at 2920 cm -1 and 2850 cm -1 at the end of 12 and 48 h respectively (Table 5), suggesting a lipid extraction as a key part by which CAGE increases penetration of molecules into the skin [51, 52]. Table 5. Effect of chemical permeation enhancers or CAGE or CAGE - P gel on absorbance at wavenumber 2850 cm -1 and 2920 cm -1PBS - phosphate buffered saline; OA - Oleic acid; PA - palmitic acid; CAGE - choline and geranate; CAGE -P - Pluronic gel with ionic liquids. Results are represented as mean ± SD (n = 3). 'a' and 'b' represents that the value is significantly different compared to CAGE-Pluronic gel treated groups for 2 and 12 h at wavenumber 2850 cm -1 (symmetric CH2 bond stretching) and 2920 cm -1 (asymmetric CH2 bond stretching) at p <0.05. Figure 8b and Table 6 shows the transition temperature (°C), change in enthalpy (∆H, J / g) and DSC thermograms for SC before and after treatment with enhancers or CAGE or CAGE - Pluronic gel, incubated at different time points. The transition temperature for untreated skin sample was found to be 70.8 ± 0.8°C with (-641.7 ± 4.7 J / g) change in enthalpy. The incubation of skin with vehicle (35% ethanol) decreased the enthalpy to 521.7 ± 24.7 and increased transition temperature to 73.7 ± 0.5°C. In general, ∆H decreased after treatment with OA or PA or CAGE or CAGE - P gel. The ∆H decreased significantly at (p < 0.05) by (~ 0.09 - fold) for CAGE and (~ 0.07 - fold) for CAGE - P gel at the end of 12 h, followed by (~ 0.06 - fold) and (~ 0.05 - fold) decrease at the end of 48 h, compared to untreated skin. The transition temperature increased for OA by (~ 1.14 - fold) or PA (~ 1.09 - fold) or CAGE - P gel (~ 1.16 - fold) treated skin samples at the end of 48 h, compared to untreated skin. Table 6. Thermotropic values for stratum corneum before and after treatment with chemical permeation enhancers or CAGE or CAGE-P gelPBS - phosphate buffered saline; OA - Oleic acid; PA - palmitic acid; CAGE - choline and geranate; CAGE -P gel - Pluronic gel with ionic liquids . Results are represented as mean ± SD (n = 3). 'a' represents that the value is significantly different compared to other groups at p <0.05. The FESEM images were shown in (Figure 8c - e) for intact or tape - stripped (removal of SC) or control (treated with 35% ethanol). The SEM images for SC after treatment with enhancers or CAGE or CAGE - P gel, incubated at different time points were arranged from (left to right) with respective to incubation time (2 h, 12 h and 48 h). The thickness of the intact skin as measured for SC, viable epidermis and dermis was 14.7 μm, 136.3 μm and 108.3 μm, respectively. The removal of SC did not significantly disturb the arrangement of underlying skin layers (Figure 8d). The control group image indicated the SC surface to be flat, relatively regular, and closely spaced with some ridgelines and zigzagging arrangement. In comparison with the control group, the SC incubated for 2 h with different formulations, showed internal bumpy wrinkles. In contrast, SC surface structure had more cracks, bigger pores, loose and irregular arrangements as shown by yellow - arrow for 12 h incubated skin samples. SC structure fissure showed significant cracks at the end of 48 h, which favored enhanced permeation of cyclosporine A across the skin.Pharmacokinetic studiesRP-HPLC was used to determine the plasma concentrations of cyclosporine A after topical application using different formulations. The lowest limit of quantitation (LLOQ) value for cyclosporine A in plasma was found to be 0.37ng / ml. The extraction of cyclosporine A from plasma was optimized from different concentrations (0.00037-18.75 μg / ml). The average recovery percentage was found to be 87.2%. TEWL was measured to understand the structural integrity of the skin before and after the application of cyclosporine A formulations. Figure 9a shows that the TEWL values for the intact skin and after 2h application of cyclosporine A dispersed in PBS + ethanol solution mixture was 8.02 ± 0.73 g / m 2 / h and 18.05 ± 1.67 g / m 2 / h, respectively. However, the TEWL value increased by ~1.2 - fold, ~1.4 - fold and ~1.5 - fold after 2h application of cyclosporine A + PA or CAGE or CAGE-pluronic gel formulation in intact skin, respectively. Laser Doppler flowmeter (LDF) allows continuous assessment of skin irritation potential of penetration enhancer by recording blood flow. The normal blood flow value in rat recorded was found to be 63.21 ± 4.1 ml / min, which slightly deviated from our earlier reported work
[27] . The blood flow values increased significantly at (p < 0.05) on the application of PBS + ethanol mixture solution and PA (Figure 9a). However, the blood flow rate increased to 85.2 ± 4.8 and 93.2 ± 4.9 ml / min after 2h application cyclosporine A + CAGE or CAGE-P gel formulation in intact skin at (p < 0.05), respectively. The irritation index calculated in terms of ratio of blood flow rate with respect to control before (1.11 ± 0.084) and after (1.33 ± 0.18) the gel formulation application did not change significantly (p > 0.05) (Figure 9b). Figure 10 shows the mean plasma concentration versus time profile of cyclosporine A after topical application in intact skin. Table 7 provides the pharmacokinetic parameters computed using WINNONLIN software for cyclosporine A administered using different formulations. Control formulation (PBS + ethanol) mixture solution resulted in absorption of cyclosporine A across the skin, with peak plasma concentration (Cmax) of 16.5 ± 0.36 μg / ml / cm 2, within 30 min after topical application. This value was found to be significantly (p < 0.05) more compared with ex - vivo studies, where 3.04 ± 0.63 μg / ml / cm 2 of cyclosporine A was found to be permeated across the porcine skin at 30 min. This is due the thickness of the SC in adult rats (17 μm) compared to the porcine skin (28 μm), used in our studies
[53] . cyclosporine A + PA application resulted in Cmax of 132.8 ± 0.3 μg / ml at tmax of 6 h at the end of 48 h. Application of CAGE formulation, significantly (p < 0.05) improved the pharmacokinetic parameters including Cmax (194.4 ± 1.2 μg / ml), t1 / 2 (16.4 ± 0.4 h) and AUC0-48 (6618.3 ± 66.8 μg.h / ml) compared with control and PA application on intact skin. However, the greatest plasma concentration and AUC were obtained with cyclosporine A + CAGE-pluronic gel formulation. It was found that 6.82 ± 0.4 mg of the total cyclosporine A applied (8.5 ± 0.8 mg) got absorbed into the systemic circulation after administration using CAGE-P gel on intact skin.Table 7. Pharmacokinetic parameters for the topical application of CsACsA - cyclosporine A; PA - Palmitic acid; CAGE -choline and geranate; CsA-CAGE -P gel- CsA loaded Pluronic gel with ionic liquids. Results are represented as mean ± SD (n = 4). 'a' and 'b' represents that the t1 / 2 and Cmax value is significantly different compared to all the groups at (p < 0.05). Efficacy studies Imiquimod induced psoriatic plaque model The phenotypic images of shaved rat back during IMQ application or with or without treatment with cyclosporine A-CAGE gel, are shown in Figure 11. IMQ-application showed induction of psoriasis on the skin-surface with scaly lesions and slight erythema, which was found to be more pronounced after 4 days. The level of sebum on the skin surface for the IMQ-applied group was reduced which caused the skin to appear darker
[54] . Similar observations were made with respect to untreated group, where the intensity of scaling and erythema did not improve significantly. The effect of CsA-CAGE-P gel or i.v. dose of cyclosporine (prepared by dissolving CsA; 1% in the mixture of polyoxyethylated castor oil; 65% w / v and ethanol; 34% w / v) on the induced psoriatic skin, administered by tail vein injection is also shown. The effect of CsA topical gel was much better compared to the i.v. route of administration, which may be due to the increased permeation of cyclosporine through pluronic gel carrier, containing CAGE and PEG-400. The TEWL and LDF values were found to be 11.7 ± 1.0 g / m 2 / h and 63.14 ± 0.06 ml / min for control group. The IMQ-applied group had a significantly (p<0.05) higher values of TEWL (29.5 ± 2.0 g / m 2 / h) and LDF (101 ± 7 ml / min), associated with a degree of barrier damage. However, these values decreased with the application of topical gel of cyclosporine A (Figure 12 b, c). Body weights measured for consecutive 16 days of study, is shown in figure 12a. Significant decline in the body weight was observed from the 4 th day of the IMQapplication compared to their initial body weight. In case of control group, continuous increase in the body weight was observed from 0 th to 8 th day. The application of topical CsA-CAGE-P gel, significantly (p<0.05) increased the body weight, compared to psoriatic induced or untreated group. As diet is the determining factor affecting weight, the amount of food and water intake of rat was weighed throughout the study, every 24 h after the application of respective formulations. Figure 13 a show reduction in the food intake caused by IMQ from 4 th to 8 th day. On the other hand, the water intake was reduced from the 1 st day, and was the lowest on the 6 th - 8 th day (Figure 13 b). This followed a similar trend as that of the food intake. However, significant (p<0.05) increase in the food and water intake for the rats, was observed from 12 th to 16 th day, after topical gel of cyclosporine A. Measurement of rat body temperature by infrared thermal image Temperature assessment is a signal, closely associated with inflammation. Figure 14 shows the infrared thermal images captured for the psoriatic or untreated skin or treated skin after the topical application of IMQ or CsA-CAGE-P gel or CsA-i.v. administration. The normal body temperature measured in control group was 37.4 ± 0.36°C. IMQ-induced psoriatic group showed decrease in the body temperature of the rat compared to control group. Nevertheless, the application of topical gel or i.v. dose of cyclosporine A increased the body temperature on the 12 th day (35.5 ± 0.5°C) and 14 th day (33.7 ± 1.5°C) which attained to 36.3 ± 0.8°C and 34.1 ± 1.3°C at the end of 16 th day. However, the body temperature for the untreated group was measured to be the same (33.6 ± 1.4°C) as that of the IMQ-applied group (33.2 ± 0.6°C), at the end of 16 th day. PASI scoring Assessment of PASI scores is an important parameter for determining the severity of disease. PASI score of all the treatment groups were compared with the control groups. As shown in Figure 15, the severity increased with the continuous application of IMQ and the PASI score peaked on 8 th day. After treatment with different formulations containing 1% cyclosporine A-CAGE-Pgel or i.v. solution, the symptoms were alleviated with different levels. Reduction in the PASI score indicated the degree of healing of the treatment. The PASI score for consistent reduction in erythema and scaling in the topical gel was observed (Figure 15a, b). The PASI score of erythema for the skin without any treatment was similar to that of IMQ-applied group. However, the PASI score for scaling was constant in the untreated group, with no significant decrease throughout the course of the study. Skin thickness measured for the control group was 1.25 ± 0.03 mm. For IMQ-applied group, the skin thickness increased by ~1.11 - fold. Figure 15 c shows the skin thickness of 1.29 ± 0.01 mm and 1.31 ± 0.02 mm for CsA-CAGE-P gel or i.v. dose of cyclosporine after 8 days of consecutive treatment. For the untreated group, the skin thickness measured was found to be 1.31 ± 0.02 mm. Spleen to body weight ratios (SBR) were determined in which the IMQ-applied group showed the higher value of 0.004 ± 0.0003 in comparison to other groups (Figure 15 d). Topical use of IMQ increases spleen weight which is confirmed by the higher SBR values
[55] . Treatment groups showed reduction in spleen weight to body weight ratio with respect to IMQ and untreated group. CsA-CAGE-P gel and i.v. dose showed SBR of 0.003 ± 0.0002 and 0.003 ± 0.0003, respectively. Decline in SBR in treatment groups might be due to the neutralization effect of IMQ. The degree of splenomegaly was evident from the images captured for the gross changes in the spleen length (Figure 13 c). The size of the spleen was measured to be 3.8 ± 0.2 cm for IMQ-applied psoriatic condition which was significantly more (p < 0.05) compared to control group (3.3 ± 0.1 cm). However, for CsACAGE-P gel and CsA-i.v. formulations, the spleen length decreased by ~1.17 - fold and 1.08 - fold respectively (Figure 13 d). Histological analysis Histopathology images of skin samples isolated from representative animals of each group were observed and compared (Figure 16). Control group represents healthy animal skin characterized by intact stratum corneum with thin epidermal layer (40.5 ± 8.92μm) (Figure 16a, f). The IMQ-applied group shows significant (p<0.05) thickening of epidermis (hyperkeratosis) by ~1.5 - fold (Figure 16b, g), compared to control group. The images also show detachment of stratum corneum from the epidermal layer. Figure 16c, h shows no marked improvement in the appearance of stratum corneum or viable epidermis for untreated group. However, significant reduction in epidermal thickness was observed in CsA-CAGE-P gel group (Figure 16d, i), while the effect was less prominent in CsA-i.v. group followed by absence of stratum corneum (Figure 16e, j) Ex-vivo skin permeation studies across rat skinThe average thickness of excised rat dorsal skin used for ex vivo permeation studies was found to be 235 ± 5 μm, 280 ± 3 μm, 273 ± 2.5 μm, 265 ± 2.3 μm and 269 ± 3.1 μm for control, IMQ-applied, without treatment, CsA-CAGE-P gel and i.v. dose groups, respectively. The average TEWL and TEER for control group was found to be 10.7 ± 1.1 g / m 2 / h and 16.3 ± 2.6 kΩ / cm 2, respectively. However, the TEWL values were significantly (p<0.05) higher for IMQ- applied and no-treatment groups, with decrease in the TEER values. In contrast, TEWL values decreased to 12.3 ± 1.5 g / m 2 / h for CsA-CAGE-P gel treated group and to 18.2 ± 1.3 g / m 2 / h for i.v. dose of CsA. Also, TEER values for CsACAGE-P gel group and i.v. dose was found to be 14.7 ± 2.6 kΩ / cm 2 and 9.8 ± 1.8 kΩ / cm 2, The calibration curve for cyclosporine A was developed in skin matrix. The lower limit of quantitation (LLOQ) was found to be 0.35 μg / ml. The percentage recovery was in the range (78 - 85 %), for the concentration ranging from 0.1 - 50 μg / ml. Ex vivo skin permeation studies showed that cyclosporine A permeate across healthy skin for up to 48 h (Figure 17a). However, the amount of cyclosporine A retained in stratum corneum, and viable skin was found to be 1314± 100 μg / g and 2224 ± 320 μg / g, respectively (Figure 17b). The cumulative amount of cyclosporine A permeated across the psoriatic skin was 5046.3 ± 124.06 μg / cm 2, which was significantly (p<0.05) more compared to all the other treated groups. The penetration barrier deterioration may be expected to accelerate drug delivery into the skin, augmenting the risk of over-absorption. It also showed significantly (p < 0.05) greater flux, diffusivity and permeation coefficient. In contrast, the cumulative amount of cyclosporine A permeated across untreated skin decreased by ~1.15 - fold. The amount of cyclosporine A retained in the viable epidermis for IMQ-applied psoriatic skin was 2810 ± 332 μg / g, which was significantly (p<0.05) more compared to other groups. This increased retention may be due to the increased epidermal thickness by abnormal keratinization in psoriasis model, which creates a longer pathway through which the drugs have to diffuse
[56] . The cumulative amount permeated across the CsA-CAGE-P gel treated skin and i.v. administered was 3851 ± 37 μg / cm 2 and 3794 ± 122 μg / cm 2. The amount of CsA retained in the viable epidermis, decreased by ~1.13 - fold and ~1.21 - fold for CsA-CAGE-P gel treated and i.v. injected groups, respectively when compared with IMQ-applied psoriatic skin. Conclusions The data reported in the present application underline the importance of chemical enhancers on cyclosporine A permeation across and into the skin. The free cyclosporine A did not permeate across the intact porcine skin. However, cyclosporine A was able to permeate across the rat skin as observed in pharmacokinetic studies. The co-treatment of intact skin with cyclosporine A and PA provided greater permeation enhancement compared with co-treatment with cyclosporine A and OA. Ionic liquids increased the diffusivity significantly across the stratum corneum, thereby resulting in enhanced permeation of clinically relevant concentration of cyclosporine A. On the other hand, saturated solution of cyclosporine A in the mixture of polyethylene glycol and ionic liquids enhanced the flux of cyclosporine A across skin without influencing the diffusion coefficient and overall significant increase in cyclosporine A permeation. A clinically desired cyclosporine A plasma concentration was achieved by combining ionic liquids and polyethylene glycol with cyclosporine A loaded in pluronic gel. Upon their efficacy evaluation using imiquimod induced psoriatic plaque model, the cyclosporine A-CAGE gel showed considerable efficacy by reducing the levels of inflammation, compared to the conventional cyclosporine A intravenous administration. Overall, the formulated pluronic gel containing ionic liquids is promising for enhanced transdermal delivery of cyclosporine A and proved to be efficacious in treatment of psoriasis. Although the invention has been described with reference to specific embodiments, this description is not meant to be construed in a limiting sense as it will become apparent to persons skilled in the art upon reference to the description of the invention. It is therefore, contemplated that such modifications can be made without departing from the spirit or scope of the present invention as defined.References: 1. Chen HH, Lin CC, Tung YT, Chao YH, Huang WC, Lee PY. Combination therapy of acarbose and cyclosporine a ameliorates imiquimod-induced psoriasis-like dermatitis in mice. Molecules. 2020 Jan;25(8):1822. 2. Jeong HR, Kim JY, Kim SN, Park JH. Local dermal delivery of cyclosporin A, a hydrophobic and high molecular weight drug, using dissolving microneedles. European Journal of Pharmaceutics and Biopharmaceutics. 2018 Jun 1; 127:237-43. 3. Paul CF, Ho VC, McGeown C, Christophers E, Schmidtmann B, Guillaume JC, Lamarque V, Dubertret L. Risk of malignancies in psoriasis patients treated with cyclosporine: a 5-y cohort study. Journal of investigative dermatology. 2003 Feb 1;120(2):211-6. 4. Carreras JJ, Tapia-Ramirez WE, Sala A, Guillot AJ, Garrigues TM, Melero A. Ultraflexible lipid vesicles allow topical absorption of cyclosporin A. Drug delivery and translational research. 2020 Apr;10(2):486-97. 5. Benigni M, Pescina S, Grimaudo MA, Padula C, Santi P, Nicoli S. Development of microemulsions of suitable viscosity for cyclosporine skin delivery. International journal of pharmaceutics. 2018 Jul 10;545(1-2):197-205. 6. Choi HK, Flynn GL, Amidon GL. Percutaneous absorption and dermal delivery of cyclosporin A. Journal of pharmaceutical sciences. 1995 May;84(5):581-3. 7. Devaux S, Castela A, Archier E, Gallini A, Joly P, Misery L, Aractingi S, Aubin F, Bachelez H, Cribier B, Jullien D. Adherence to topical treatment in psoriasis: a systematic literature review. Journal of the European Academy of Dermatology and Venereology. 2012 May; 26:61-7. 8. Ellis CN, Fradin MS, Messana JM, Brown MD, Siegel MT, Hartley AH, Rocher LL, Wheeler S, Hamilton TA, Parish TG, Ellis-Madu M. Cyclosporine for plaque-type psoriasis: results of a multidose, double-blind trial. New England Journal of Medicine. 1991 Jan 31;324(5):277-84. 9. Erramreddy VV, Ghosh S. Influence of emulsifier concentration on nano emulsion gelation. Langmuir. 2014 Sep 23;30(37):11062-74. 10. Frušić‐Zlotkin M, Soroka Y, Tivony R, Larush L, Verkhovsky L, Bregegere FM, Neuman R, Magdassi S, Milner Y. Penetration and biological effects of topically applied cyclosporin A nanoparticles in a human skin organ culture inflammatory model. Experimental dermatology. 2012 Dec;21(12):938-43. 11. Grimaudo MA, Pescina S, Padula C, Santi P, Concheiro A, Alvarez-Lorenzo C, Nicoli S. Poloxamer 407 / TPGS mixed micelles as promising carriers for cyclosporine ocular delivery. Molecular pharmaceutics. 2018 Feb 5;15(2):571-84. 12. Guo J, Ping Q, Sun G, Jiao C. Lecithin vesicular carriers for transdermal delivery of cyclosporin A. International Journal of Pharmaceutics. 2000 Jan 25;194(2):201-7. 13. Hermann RC, Taylor RS, Ellis CN, Williams A, Weiner ND, Flynn GL, Annesley TM, Voorhees JJ. Topical ciclosporin for psoriasis: in vitro skin penetration and clinical study. Skin Pharmacology and Physiology. 1988;1(4):246-9. 14. Hirano T, Oka K, Umezawa Y, Hirata M, Oh‐i T, Koga M. Individual pharmacodynamics assessed by antilymphocyte action predicts clinical cyclosporine efficacy in psoriasis. Clinical Pharmacology & Therapeutics. 1998 Apr;63(4):465-70. 15. Walunj M, Doppalapudi S, Bulbake U, Khan W. Preparation, characterization, and in vivo evaluation of cyclosporine cationic liposomes for the treatment of psoriasis. Journal of liposome research. 2020 Jan 2;30(1):68-79. 16. Koo K, Jeon C, Bhutani T. Beyond monotherapy: a systematic review on creative strategies in topical therapy of psoriasis. Journal of Dermatological Treatment. 2017 Nov 17;28(8):702-8. 17. Ramadon D, McCrudden MT, Courtenay AJ, Donnelly RF. Enhancement strategies for transdermal drug delivery systems: Current trends and applications. Drug Delivery and Translational Research. 2022 Apr;12(4):758-91. 18. Jose A, Mandapalli PK, Venuganti VV. Liposomal hydrogel formulation for transdermal delivery of pirfenidone. Journal of liposome research. 2016 Apr 2;26(2):13947. 19. Alexander A, Dwivedi S, Giri TK, Saraf S, Saraf S, Tripathi DK. Approaches for breaking the barriers of drug permeation through transdermal drug delivery. Journal of Controlled Release. 2012 Nov 28;164(1):26-40. 20. Williams AC, Barry BW. Terpenes and the lipid-protein-partitioning theory of skin penetration enhancement. Pharmaceutical research. 1991 Jan;8(1):17-24. 21. Zhao K, Singh J. Mechanisms of percutaneous absorption of tamoxifen by terpenes: eugenol, D-limonene and menthone. Journal of controlled release. 1998 Nov 13;55(23):253-60. 22. Kunta JR, Goskonda VR, Brotherton HO, Khan MA, Reddy IK. Effect of menthol and related terpenes on the percutaneous absorption of propranolol across excised hairless mouse skin. Journal of pharmaceutical sciences. 1997 Dec;86(12):1369-73. 23. Ongpipattanakul B, Burnette RR, Potts RO, Francoeur ML. Evidence that oleic acid exists in a separate phase within stratum corneum lipids. Pharmaceutical research. 1991 Mar;8(3):350-4. 24. Pedro SN, R. Freire CS, Silvestre AJ, Freire MG. The role of ionic liquids in the pharmaceutical field: An overview of relevant applications. International Journal of Molecular Sciences. 2020 Nov 5;21(21):8298. 25. Touitou E, Godin B, Karl Y, Bujanover S, Becker Y. Oleic acid, a skin penetration enhancer, affects Langerhans cells and corneocytes. Journal of controlled release. 2002 Apr 23;80(1-3):1-7. 26. Sultan A, Sokolove PM. Palmitic acid opens a novel cyclosporin A-insensitive pore in the inner mitochondrial membrane. Archives of Biochemistry and Biophysics. 2001 Feb 1;386(1):37-51. 27. Datta D, Panchal DS, Venuganti VV. Transdermal delivery of vancomycin hydrochloride: Influence of chemical and physical permeation enhancers. International Journal of Pharmaceutics. 2021 Jun 1; 602:120663. 28. Lei Z, Chen B, Koo YM, MacFarlane DR. Introduction: ionic liquids. Chemical Reviews. 2017 May 24;117(10):6633-5. 29. Adawiyah N, Moniruzzaman M, Hawatulaila S, Goto M. Ionic liquids as a potential tool for drug delivery systems. MedChemComm. 2016;7(10):1881-97. 30. Banerjee A, Ibsen K, Iwao Y, Zakrewsky M, Mitragotri S. Transdermal protein delivery using choline and geranate (CAGE) deep eutectic solvent. Advanced healthcare materials. 2017 Aug;6(15):1601411. 31. Kulkarni SS, Aloorkar NH. Smart polymers in drug delivery: an overview. J. Pharm. Res. 2010 Jan;3(1):100-8. 32. Almeida H, Amaral MH, Lobão P, Lobo JM. Pluronic F-127 and Pluronic Lecithin Organogel (PLO): main features and their applications in topical and transdermal administration of drugs. Journal of Pharmacy & Pharmaceutical Sciences. 2012 Oct 29;15(4):592-605. 33. MIYAZAKI S, TAKEUCHI S, YOKOUCHI C, TAKADA M. Pluronic F-127 gels as a vehicle for topical administration of anticancer agents. Chemical and pharmaceutical bulletin. 1984 Oct 25;32(10):4205-8. 34. Berti JJ, Lipsky JJ. Transcutaneous drug delivery: a practical review. In Mayo Clinic Proceedings 1995 Jun 1 (Vol. 70, No. 6, pp. 581-586). Elsevier. 35. Burnham R, Gregg R, Healy P, Steadward R. The effectiveness of topical diclofenac for lateral epicondylitis. Clinical journal of sport medicine. 1998 Apr 1; 8:78-81. 36. Giordano J, Daleo C, Sacks SM. Topical ondansetron attenuates nociceptive and inflammatory effects of intradermal capsaicin in humans. European journal of pharmacology. 1998 Jul 31;354(1): R13-4. 37. Kumar R, Katare OP. Lecithin organogels as a potential phospholipid-structured system for topical drug delivery: a review. Aaps Pharmscitech. 2005 Jun;6(2): E298-310. 38. Glisson JK, Wood RL, Kyle PB, Cleary JD. Bioavailability of promethazine in a topical Pluronic lecithin organogel: A pilot study. International journal of pharmaceutical compounding. 2005 May 1;9(3):242. 39. Morales ME, Clares B, Lopez-Viota M, Ruiz MA. Preparation, characterization, and in vitro release of new transdermal methimazole as alternative to oral delivery. Drug delivery. 2009 Jan 1;16(1):1-0. 40. Vigato AA, Querobino SM, de Faria NC, Candido AC, Magalhães LG, Cereda CM, Tofoli GR, Campos EV, Machado IP, Fraceto LF, de Sairre MI. Physico-chemical characterization and biopharmaceutical evaluation of lipid-poloxamer-based organogels for curcumin skin delivery. Frontiers in pharmacology. 2019 Sep 12; 10:1006. 41. Zhao X, Zhou YQ, Potharaju S, Lou H, Sun HM, Brunson E, Almoazen H, Johnson J. Development of a self microemulsifying tablet of cyclosporine-a by the liquisolid compact. Int. J. Pharm. Sci. Res. 2011;2(9):2299-308. 42. Wong RS, Dodou K. Effect of drug loading method and drug physicochemical properties on the material and drug release properties of poly (ethylene oxide) hydrogels for transdermal delivery. Polymers. 2017 Jul;9(7):286. 43. Tanojo H, Boelsma E, Junginger HE, Ponec M, Boddec HE. In vivo human skin permeability enhancement by oleic acid: a laser Doppler velocimetry study. Journal of controlled Release. 1999 Mar 8;58(1):97-104. 44. Panchagnula R, Bokalial R, Sharma P, Khandavilli S. Transdermal delivery of naloxone: skin permeation, pharmacokinetic, irritancy and stability studies. International journal of pharmaceutics. 2005 Apr 11;293(1-2):213-23. 45. Kjær TN, Thorsen K, Jessen N, Stenderup K, Pedersen SB. Resveratrol ameliorates imiquimod-induced psoriasis-like skin inflammation in mice. PloS one. 2015 May 12;10(5):e0126599. 46. Marwah MK, Shokr H, Sanchez-Aranguren L, Badhan RK, Wang K, Ahmad S. Transdermal Delivery of a Hydrogen Sulphide Donor, ADT-OH Using Aqueous Gel Formulations for the Treatment of Impaired Vascular Function: An Ex Vivo Study. Pharmaceutical Research. 2022 Jan 27:1-2. 47. Mesnukul A, Yodkhum K, Phaechamud T. Solid dispersion matrix tablet comprising indomethacin-PEG-HPMC fabricated with fusion and mold technique. Indian Journal of Pharmaceutical Sciences. 2009 Jul;71(4):413. 48. Parhi R. Development and optimization of pluronic F127 and HPMC based thermosensitive gel for the skin delivery of metoprolol succinate. Journal of Drug Delivery Science and Technology. 2016 Dec 1; 36:23-33. 49. Adhikari B, Nanda J, Banerjee A. Pyrene‐containing peptide‐based fluorescent organogels: inclusion of graphene into the organogel. Chemistry-A European Journal. 2011 Oct 4;17(41):11488-96. 50. Wong RS, Dodou K. Effect of drug loading method and drug physicochemical properties on the material and drug release properties of poly (ethylene oxide) hydrogels for transdermal delivery. Polymers. 2017 Jul;9(7):286. 51. Tanner EE, Ibsen KN, Mitragotri S. Transdermal insulin delivery using choline-based ionic liquids (CAGE). Journal of controlled release. 2018 Sep 28; 286:137-44. 52. Lan Y, Wang J, Li H, Zhang Y, Chen Y, Zhao B, Wu Q. Effect of menthone and related compounds on skin permeation of drugs with different lipophilicity and molecular organization of stratum corneum lipids. Pharmaceutical Development and Technology. 2016 May 18;21(4):389-98. 53. Niczyporuk M. Rat skin as an experimental model in medicine. Progress in Health Sciences. 2018; 8:223-8. 54. Lin YK, Yang SH, Chen CC, Kao HC, Fang JY. Using imiquimod-induced psoriasislike skin as a model to measure the skin penetration of anti-psoriatic drugs. PLoS One. 2015 Sep 10;10(9):e0137890. 55. Palamara F, Meindl S, Holcmann M, Luhrs P, Stingl G, Sibilia M. Identification and characterization of pDC-like cells in normal mouse skin and melanomas treated with imiquimod. The Journal of Immunology. 2004 Sep 1;173(5):3051-61. 56. Fang JY, Fang CL, Liu CH, Su YH. Lipid nanoparticles as vehicles for topical psoralen delivery: solid lipid nanoparticles (SLN) versus nanostructured lipid carriers (NLC). European Journal of Pharmaceutics and Biopharmaceutics. 2008 Oct 1;70(2):633-40.
Claims
1. A composition for transdermal drug delivery of cyclosporine A comprising ionic liquid and fatty acids as permeation enhancer in pluronic gel and gelling agent.
2. The composition as claimed in claim 1, wherein the ionic liquid comprises of cationic and a fatty acid anionic component.
3. The composition as claimed in claim 2, wherein the ionic liquid comprises of choline and geranic acid.
4. The composition as claimed in claim 3, wherein the concentration of choline is between 8-12 % w / v.
5. The composition as claimed in claim 3, wherein the concentration of geranic acid is between 15-25 % w / v.
6. The composition as claimed in claim 1, wherein the fatty acids are oleic acid or palmitic acid or in combination.
7. The composition as claimed in claim 1, wherein the pluronic gel is PluronicF-127.
8. The composition as claimed in claim 7, wherein the concentration of pluronic gel is between 2-25 % w / v.
9. The composition as claimed in claim 1, wherein the gelling agent comprises of PEG 400.
10. The composition as claimed in claim 9, wherein the concentration of PEG400 is between 2575 % w / v.
11. The composition as claimed in claim 1, wherein the Choline and geranic acid (CAGE) ionic liquids in 2:1 ratio is mixed with Pluronic gel and PEG400 to prepare the formulation of cyclosporine A (CsA).
12. The composition as claimed in claim 1 for its use in the prophylaxis or treatment of inflammation, dermatological diseases including psoriasis, atopic dermatitis and alopecia areata and also for systemic conditions including prevention of organ rejection after transplantation.
